

# BMJ Open

## Health status and needs of cancer survivors and their caregivers: Routine evaluation of attendees at Sydney Survivorship Centre clinics and programmes

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014803
Article Type:	Protocol
Date Submitted by the Author:	20-Oct-2016
Complete List of Authors:	Vardy, Janette; University of Sydney, Sydney Medical School; Concord Cancer Centre Tan, Cindy; Concord Repatriation General Hospital, Concord Cancer Centre Turner, Jane; University of Sydney, Centre for Medical Psychology and Evidence-based Medicine Dhillon, Haryana; University of Sydney, Centre for Medical Psychology and Evidence-based Medicine
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Medical management, Haematology (incl blood transfusion), Nursing, Patient-centred medicine
Keywords:	cancer survivorship, quality of life, survivorship clinic

SCHOLARONE™  
Manuscripts

Only

Health status and needs of cancer survivors and their caregivers: Routine evaluation  
of attendees at Sydney Survivorship Centre clinics and programmes

Janette L. Vardy<sup>1,2,3</sup> Cindy Tan<sup>1</sup>, Jane D Turner<sup>1,3</sup>, Haryana M. Dhillon<sup>3</sup>

<sup>1</sup> Concord Cancer Centre, Concord Hospital, Hospital Rd, Concord, NSW,  
Australia

<sup>2</sup> Sydney Medical School, University of Sydney, Concord Hospital, Hospital  
Rd, Concord, NSW, Australia

<sup>3</sup> Centre for Medical Psychology & Evidence-based Decision-making,  
University of Sydney, NSW, Australia

Janette Vardy [janette.vardy@sydney.edu.au](mailto:janette.vardy@sydney.edu.au)

Cindy Tan [cindy.tan@sswahs.nsw.gov.au](mailto:cindy.tan@sswahs.nsw.gov.au)

Jane Turner [jane.turner@sydney.edu.au](mailto:jane.turner@sydney.edu.au)

Haryana Dhillon [Haryana.dhillon@sydney.edu.au](mailto:Haryana.dhillon@sydney.edu.au)

Corresponding author:

Prof. Janette Vardy MD PhD

Concord Cancer Centre,  
Concord Repatriation General Hospital  
Hospital Rd

Concord, NSW, 2137  
Australia

Phone: +61 2 9767 5000

Fax: +61 2 9767 7934

Email: [janette.vardy@sydney.edu.au](mailto:janette.vardy@sydney.edu.au)

1  
2  
3 Abstract:

4  
5  
6  
7 Introduction:

8  
9  
10 The care of cancer survivors after primary adjuvant treatment is recognised as a  
11 distinct phase of the cancer journey. Recent research highlights the importance of  
12 lifestyle factors in treating symptoms, potentially decreasing the risk of a cancer  
13 recurrence, and modifying the risk of developing other chronic illnesses that are  
14 increased in the cancer population. Survivorship services aim to deliver care that  
15 addresses these issues.  
16  
17  
18  
19  
20  
21

22  
23 Methods:

24  
25 An observational, single centre study evaluating the physical and psychological  
26 health, symptoms, quality of life, and lifestyle (physical activity and nutrition) of  
27 early-stage cancer survivors attending the multidisciplinary Sydney Survivorship  
28 Clinic and of survivors (at any stage of the cancer journey) and caregivers  
29 participating in Sydney Survivorship Centre courses. Evaluation of patient  
30 satisfaction is also included.  
31  
32  
33  
34  
35  
36  
37

38  
39 Discussion:

40  
41 This study will provide important information regarding the health status and needs of  
42 Australian cancer survivors, and the ability of the Survivorship Centre to address  
43 these needs. These data will shape the future direction of survivorship care in  
44 Australia and facilitate the design of interventions or measures to provide better  
45 quality of care to this patient population.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Strengths and Limitations:

Strengths:

-large, longitudinal follow up with comprehensive assessment of health and well-being of cancer survivors attending a multi-disciplinary Survivorship Centre post primary adjuvant treatment

Weaknesses:

- observational cohort study
- sample size determined by number of patients attending programme

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-014803 on 9 May 2017. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

## Introduction

Until relatively recently the focus of cancer treatment and research was on the acute treatment of cancer and monitoring for disease recurrence. In 2005 the groundbreaking Institute of Medicine (IOM) Report “Lost in Transition” identified the substantial failure of current follow-up care to comprehensively address the needs of adult cancer survivors.<sup>1</sup> Through the IOM the distinct needs of adult cancer survivors have been recognised along with the importance of helping survivors live with the longer term physical, psychological, and practical effects of cancer and its treatment.<sup>1</sup>

By the broadest definition a person becomes a cancer survivor the moment they are diagnosed with cancer, a state that continues throughout the remainder of their life.<sup>1</sup>

There are estimated to be more than 25 million cancer survivors worldwide, a number that is projected to increase rapidly due to our ageing population, improved screening leading to earlier detection of cancer, and improvements in cancer treatments.

Even cancer survivors with no evidence of disease recurrence, experience greater ongoing health problems than the general population. Cancer survivors are known to be at increased risk of cardiovascular disease, type II diabetes, metabolic syndrome, and osteoporosis, in addition to the risk of a cancer recurrence or a second primary cancer.<sup>1-5</sup> There are a number of identified lifestyle risk factors associated with cancer risk and recurrence, and the chronic diseases that accompany them. These lifestyle risk factors are modifiable and include obesity, physical inactivity, smoking, and inadequate fruit and vegetable intake.<sup>6</sup>

1  
2  
3 In an attempt to better address the needs of adult cancer survivors some cancer centres  
4 have established Survivorship Services, Centres, or Clinics. These services are  
5 designed to help survivors and their caregivers better manage their disease and any  
6 lasting effects of treatment, beyond the period of acute diagnosis and treatment.<sup>5</sup> In  
7 addition, many try to facilitate survivors enacting lifestyle changes to increase their  
8 physical activity and maintain a healthy weight, in order to aid recovery, improve  
9 health related quality of life (QOL), and possibly long-term survival.<sup>7</sup> Psychological  
10 support is an important feature of most programmes.

11  
12 The IOM recommended, with support of a number of peak bodies including the  
13 American Society of Clinical Oncology (ASCO), that all cancer survivors  
14 transitioning from active to the post treatment phase should receive an individualised  
15 Treatment and Survivorship Care Plan (SCP).<sup>1</sup> This should include a summary of  
16 cancer treatment received, and recommendations regarding future clinical care and  
17 coordination, including the frequency and nature of surveillance based on the best  
18 available evidence. A number of SCP templates are freely available, including generic  
19 and disease specific templates from ASCO and Livestrong, which include information  
20 on potential late and long-term effects from the cancer and/or treatment(s). Despite  
21 recommendations from oncology organisations that SCP should be used, there is  
22 limited evidence that they improve long term outcomes for cancer survivors although  
23 survivor satisfaction with the SCP is generally high.<sup>8</sup>

24  
25 The Sydney Survivorship Centre was established in September 2013 at the Concord  
26 Cancer Centre, in Sydney. It includes: i) a multi-disciplinary survivorship clinic for  
27 patients with localised cancer who have completed primary treatment with curative  
28 intent (e.g. surgery, chemotherapy, and radiation therapy) without evidence of cancer  
29 recurrence; and, ii) a range of programmes to support lifestyle change. At the initial  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 visit patients see a multi-disciplinary team (MDT) comprising a medical oncologist or  
4 haematologist, cancer nurse specialist, dietitian, clinical psychologist, and accredited  
5 exercise physiologist (AEP). Prior to attendance at each clinic, patients complete a  
6 number of questionnaires assessing symptoms, physical activity, diet, QOL and well-  
7 being, and are asked to fill in an evaluation after each clinic. Education regarding  
8 healthy lifestyle and encouragement to maintain a healthy weight are an important  
9 focus of every clinic. An individualised SCP is developed for each oncology patient.  
10  
11 Approximately two thirds of survivors attend the clinic once and then return to their  
12 regular medical team for ongoing follow up. The remainder continue follow up  
13 through the Survivorship Clinic. On subsequent visits they see the medical oncologist  
14 and cancer nurse specialist specific to their tumour type, with referral to other health  
15 professionals as required.  
16  
17

18  
19 In response to the high proportion of survivors who were overweight or obese, and the  
20 increasing evidence supporting obesity as a risk factor for cancer recurrence,<sup>9</sup> we  
21 established a weight management clinic focused on dietary modification, exercise and  
22 behavioural change for those with early stage solid tumours. The intervention was  
23 based on a recent systematic review that reported dietary modification involving  
24 restrictions of energy and fat intake, and promotion of exercise and behavioural  
25 changes were the key components for successful weight loss and maintenance.<sup>10</sup>  
26  
27  
28

29  
30 The Sydney Survivorship Centre opened the Survivorship Cottage in May 2014. The  
31 cottage is located in the grounds of the hospital, away from the main buildings, and  
32 surrounded by gardens and furnished in a homely manner. This is where the majority  
33 of the courses are held for cancer survivors at any stage of their cancer journey, and  
34 their caregivers, with a focus on healthy lifestyle and well-being. The Exercise and  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Nutrition Routine Improving Cancer Health (ENRICH)<sup>11</sup> programme is a 6-week  
4 exercise and healthy eating course offered in collaboration with the Cancer Council  
5 New South Wales (NSW) and held regularly throughout the year. Other courses  
6 include: Mindfulness Meditation, Medical QiGong, yoga, acupuncture, music and art  
7 therapy, as well as scrap-booking, card making and individual one-off workshops. In  
8 addition we provide support groups and public fora on topics of interest to cancer  
9 patients and their caregivers and families.  
10  
11

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Research is an integral component of the Survivorship Centre. Our major research  
aims to: (i) determine the health status, needs, symptoms, QOL and lifestyle  
characteristics of cancer survivors attending the Sydney Survivorship Clinic or  
participating in courses; (ii) evaluate changes over time in these variables, (iii)  
determine risk factors that may affect cancer survivors' clinical outcomes (e.g.  
metabolic syndrome, obesity, inactivity); (iv) evaluate patients' and/or their  
caregivers/family members' experience with services offered by the Sydney  
Survivorship Centre; and (v) evaluate the impact of the multidisciplinary team (MDT)  
approach in addressing cancer survivors' needs.

#### Methods and Patient Population

This is a single site, longitudinal study led by the Survivorship Research Group  
(SuRG), University of Sydney and the Sydney Survivorship Centre, Concord Cancer  
Centre. Ethics approval has been obtained from Concord Repatriation General  
Hospital Human Research Ethics Committee (HREC/14/CRGH/23). Patient reported  
outcome data are collected as part of standard care and for quality assurance. Patients  
attending clinics and courses at the Sydney Survivorship Centre are given the option  
of a tick box to "opt of out" if they do not wish their de-identified data to be used for



1  
2  
3 research purposes.  
4

5  
6 The Sydney Survivorship Centre (SSC) clinic commenced in September 2013 and  
7  
8 courses were introduced gradually from this time.  
9

10  
11  
12 Eligibility:

13  
14 Medical oncology or haematology patients who have completed primary adjuvant  
15  
16 treatment for early stage cancer and have no evidence of a cancer recurrence are  
17  
18 eligible to attend the Survivorship Clinic. Breast cancer patients may be receiving  
19  
20 hormonal treatment and/or targeted therapy such as trastuzumab. Figure 1 depicts the  
21  
22 referral pathway.  
23  
24

25  
26  
27 Procedure:

28  
29 Prior to attending the Survivorship clinic patients are sent a package containing  
30  
31 printed Patient Reported Outcome (PRO) Questionnaires assessing symptoms,  
32  
33 psychological well-being, distress, QOL, physical activity, dietary intake and  
34  
35 performance status. They are asked to bring the completed questionnaires to their  
36  
37 appointment. Those with incomplete questionnaires are asked to finalise them during  
38  
39 the clinic visit. Patients with insufficient English or poor literacy skills can have  
40  
41 assistance from a health translator, family members, or clinic staff during the clinic  
42  
43 appointment.  
44  
45

46  
47  
48 Medical information and weight history are obtained from the medical record.

49  
50 Anthropometry (height and weight) is obtained at the initial visit by clinic staff. A

51  
52 SCP is prepared for oncology patients prior to their initial visit, by either the medical  
53  
54 oncologist or registrar. This plan is refined with the patient after consultation with the  
55  
56  
57  
58  
59  
60

1  
2  
3 MDT members, and a copy posted to them after the clinic. Haematology patients  
4  
5 receive a detailed letter from the haematologist with recommendations rather than a  
6  
7 formal Survivorship care plan.  
8  
9

10  
11 Patients are asked to complete an evaluation form after each clinic visit. In addition,  
12  
13 those who have given verbal permission to be contacted subsequently will be asked to  
14  
15 complete a satisfaction survey over the phone or in person to provide feedback on  
16  
17 how useful the Survivorship Care Plan has been, how they used it, and if it has been  
18  
19 revised. This will be approximately 6 months after their initial visit. A subset of  
20  
21 patients will be invited to participate in a qualitative interview aimed to explore their  
22  
23 experience of the survivorship service.  
24  
25  
26  
27  
28

29  
30 All patients and their caregivers attending the Survivorship Centre (SSC) courses are  
31  
32 asked to complete questionnaires prior to commencing, and at the conclusion, of  
33  
34 courses requiring more than one visit.  
35

36 Measures:

37  
38 Outcome measures used in this study are comprehensive assessments of patient self-  
39  
40 report symptoms, QOL, distress, and lifestyle factors. The schedule of assessments  
41  
42 and details of measures are outlined in Table 1.  
43  
44  
45  
46

47 Endpoints:

48  
49 The global aim of this multi-faceted project is to evaluate the impact of the Sydney  
50  
51 Survivorship Centre Clinic and Programmes on patients attending the clinic, and  
52  
53 survivors and/or their caregivers participating in programmes. We aim to assess  
54  
55 changes in the endpoints, stated below, over time:  
56  
57  
58  
59  
60

*Survivorship Clinic*

- incidence and severity of symptoms that may be associated with cancer and/or treatment – as assessed by the Patient’s Disease and Treatment Assessment Form<sup>12</sup>
- distress - as assessed by the Distress thermometer<sup>13</sup>
- quality of life as assessed by the FACT-G<sup>14</sup>
- physical activity and sedentary behaviour- as assessed by the Active Australia Exercise Questionnaire<sup>15</sup> and the Sitting Questionnaire<sup>16</sup> and AEP consultation.
- dietary intake and behaviour – as assessed by an in-house 3-day food diary and Food Questionnaire and dietitian consultation
- Eastern Co-operative Oncology Group Performance Status (ECOG Performance Status)<sup>17</sup>- as assessed by both clinician and participant
- Clinical assessments: medical and physical assessment by doctor and nurse; fear of cancer recurrence assessed by Clinical Psychologist, anthropometric assessment.
- Effectiveness of MDT in addressing survivors’ needs measured by change in outcomes, e.g., QOL, sedentary behaviour, etc
- Use and effectiveness of Treatment and Survivorship Care Plan (SCP). To determine the incidence of patients attending the Survivorship Clinic who: receive a survivorship plan; are referred to other health professionals from clinic; use the SCP (e.g. show other health professionals, carry out the clinic recommendations). Whether patients found the SCP helpful, did it contain new information and suggestions for improvement.

- Clinical progress as determined by results of clinical examination, blood tests and/or imaging ordered as part of standard of care.
- Effectiveness of surveillance system: Total number of cases of recurrence of cancer
- Patients' experience with Sydney Survivorship Clinic

*Specific SSC programmes:*

Weight management programme:

- Facilitated and supervised by AEP and Dietitian
  - attendance (number of enrolees, proportion completing programmes, reasons for non-attendance)
  - QOL, symptoms, food intake, exercise behaviour, knowledge/practice and changes compared to baseline assessment
  - Lifestyle outcomes: anthropometry measurements, vital signs, aerobic capacity and muscular strength - Week 0, 12, 26 and then 6 monthly until 2 years.
  - blood results collected as part of standard of care
  - patient experience as measured by a satisfaction survey and interview
- See Appendix Table 1 for full details.

Mindfulness, QiGong, Yoga, Music therapy, Art therapy or similar courses:

- Attendance (number of enrolees, proportion completing programmes, reasons for non-attendance)
- Clinical outcomes: demographics, cancer diagnosis and treatment,
- Symptoms: assessed by the Patient's Disease and Treatment Assessment Form<sup>12</sup>
- Psychosocial outcomes (completed pre and post intervention):

1  
2  
3 QOL and fatigue assessed by the FACT-General (G)<sup>14</sup> and Fatigue (F)  
4 subscale<sup>18</sup>  
5  
6

7 Spiritual well-being assessed by the FACT-Spiritual<sup>19</sup> (for mindfulness, yoga  
8 medical Qigong, acupuncture and medical well-being courses)  
9

10 Symptoms of anxiety and depression –assessed by the Hospital Anxiety and  
11 Depression Scale (HADS)<sup>20</sup>  
12

13 Distress – assessed by the Distress Thermometer<sup>13</sup>  
14

- 15 • ECOG performance status (patient rated)<sup>17</sup>
  - 16 • Participant satisfaction questionnaire – at end of programme only
- 17  
18  
19  
20  
21  
22

#### 23 In-depth Qualitative exploration of patient experience:

24 Cancer survivors and/or caregivers/family members will be invited to participate in  
25 focus group(s) and/or interviews to provide in-depth feedback about their experience  
26 of SSC services, and information about unmet needs to guide the direction of the SSC  
27 clinic or programmes. Consenting individuals will attend a focus group meeting, a  
28 face-to-face interview, or a telephone interview with staff of the University of Sydney  
29 who are not involved in their clinical care.  
30  
31  
32  
33  
34  
35  
36  
37

#### 38 Data analysis and statistical issues

39 The sample size will be determined by attendance of consenting patients at clinics and  
40 courses.  
41  
42  
43  
44

45 Data are entered into a specifically designed REDCap<sup>TM</sup> database. Simple descriptive  
46 methods will be used to report incidence and, where appropriate, severity of patient  
47 reported outcomes, physical activity, and dietary behaviour for cancer survivors. A  
48 comparison of change over time in symptoms and behaviours will be performed.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Discussion:**

Survivorship concerns are increasingly recognised as poorly addressed in many standard follow-up appointments. There is considerable debate and a lack of evidence regarding how best to follow up cancer survivors. Multi-disciplinary clinics have the capacity to provide holistic care with a focus on education concerning lifestyle issues, prevention of long term side effects and psychological well being; but they are resource intensive for staff.

A physically active lifestyle and healthy weight have been shown in observational studies to decrease the risk of common cancers and cancer recurrence. Studies have also shown that physical activity and healthy nutrition can improve symptoms associated with cancer treatment, and decrease the risk of chronic diseases that are commonly found in cancer survivors; including metabolic syndrome, obesity, type II diabetes, cardiovascular disease and osteoporosis.<sup>21</sup> Although a number of cancer organisations have published recommendations regarding exercise and weight, the majority of cancer patients are overweight or obese, and most do not meet the guidelines of 150 minutes/week of moderate intensity physical activity, two sessions of resistance exercise/week and minimising sedentary activities, despite the increasing evidence for benefit.<sup>21 22</sup> This suggests that cancer survivors require additional support and education to facilitate their instituting important lifestyle changes.

The Sydney Survivorship Centre has the potential to improve physical and psychological well-being and QOL for cancer survivors. This study will obtain unique data regarding the impact of a multi-disciplinary team Survivorship clinic for cancer patients who have completed primary adjuvant treatment, and evaluation of the courses offered by the Sydney Survivorship Centre for patients at any stage of the

1  
2  
3 cancer journey and their caregivers/family. This will help determine whether  
4  
5 assessing health status, providing education and lifestyle programmes facilitates  
6  
7 adoption and adherence to a healthy lifestyle, and whether this can lead to  
8  
9 improvement in well-being. Further, it will evaluate the Survivorship care plans  
10  
11 through usage in routine clinical practice, as well as gaining information about who  
12  
13 uses the Sydney Survivorship Centre programmes, and patient (and caregiver)  
14  
15 satisfaction with the clinic and courses.  
16  
17  
18  
19  
20

#### 21 Conclusions:

22  
23 Survivorship services are expanding in Australia and globally. The Sydney  
24  
25 Survivorship Centre is the only multidisciplinary clinic of its kind in Australia. This  
26  
27 study will provide important information about the health status of Australian cancer  
28  
29 survivors, and enable us to better understand the symptoms, lifestyle and risk factors  
30  
31 of our patient population. This will facilitate the design of supportive measures or  
32  
33 interventions to better address these issues.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Author Contributions:

4  
5 J. Vardy: study concept and design, and writing of the protocol and manuscript.  
6 C. Tan: study concept and design, and writing of the protocol and manuscript.  
7 J. Turner: study concept and design, and writing of the protocol and manuscript.  
8 H. Dhillon: study concept and design, and writing of the protocol and manuscript.  
9

10  
11 Competing Interests:

12 None of the authors have any conflicts of interest to declare.  
13

14 Funding Statement:

15  
16 This research is supported by a grant from the National Breast Cancer Foundation,  
17 Australia, in the form of a Practitioner Fellowship to Prof. Janette Vardy. (PRAC-15-  
18 003).  
19

20  
21 Data Sharing:

22 This is a protocol for a longitudinal study so unpublished data is not available for  
23 sharing.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## References

1. Hewitt ME, Ganz PA, Institute of Medicine (U.S.), et al. From cancer patient to cancer survivor : lost in transition : an American Society of Clinical Oncology and Institute of Medicine Symposium. Washington, D.C.: National Academies Press 2006.
2. Baade P, Fritschi L, Eakin E. Non-cancer mortality among people diagnosed with cancer (Australia). *Cancer Causes and Control* 2006;17:287-97.
3. Holmes MD, Chen WY, Feskanich D, et al. Physical activity and survival after breast cancer diagnosis. *JAMA* 2005;293(20):2479-86. doi: 10.1001/jama.293.20.2479
4. Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical Activity and Survival After Colorectal Cancer Diagnosis. *J Clin Oncol* 2006;24(22):3527-34. doi: 10.1200/jco.2006.06.0855
5. McCabe MS, Bhatia S, Oeffinger KC, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31(5):631-40. doi: 10.1200/JCO.2012.46.6854 [published Online First: 2013/01/09]
6. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington DC: World Cancer Research Fund/American Institute Cancer Research, 2007.
7. Hewitt ME, Greenfield S, Stovall E, et al. From cancer patient to cancer survivor : lost in transition. Washington, D.C.: National Academies Press 2006.
8. Kinnane N, Moore, R., Jefford, M., Piper, A., Nolte, L. Survivorship care plans: literature review. Melbourne: Australian Cancer Survivorship Centre, Peter MacCallum, Cancer Centre, 2015.
9. Demark-Wahnefried W, Platz EA, Ligibel JA, et al. The role of obesity in cancer survival and recurrence. *Cancer Epidemiology Biomarkers & Prevention* 2012;21(8):1244-59. doi: 10.1158/1055-9965.epi-12-0485
10. Ramage S, Farmer A, Apps Eccles K, et al. Healthy strategies for successful weight loss and weight maintenance: a systematic review. *Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme* 2014;39(1):1-20. doi: 10.1139/apnm-2013-0026 [published Online First: 2014/01/05]
11. James EL, Stacey FG, Chapman K, et al. Impact of a nutrition and physical activity intervention (ENRICH: Exercise and Nutrition Routine Improving Cancer Health) on health behaviors of cancer survivors and carers: a pragmatic randomized controlled trial. *BMC cancer* 2015;15 doi: 10.1186/s12885-015-1775-y
12. Stockler MR, O'Connell R, Nowak AK, et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. *The lancet oncology* 2007;8(7):603-12. doi: 10.1016/S1470-2045(07)70148-1
13. Tuinman MA, Gazendam-Donofrio SM, Hoekstra-Weebers JE. Screening and referral for psychosocial distress in oncologic practice: use of the Distress Thermometer. *Cancer* 2008;113(4):870-8. doi: 10.1002/cncr.23622 [published Online First: 2008/07/12]

14. Cella D, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. *J Clin Oncol* 1993;11(3):10.
15. Brown WJ, Trost SG, Bauman A, et al. Test-retest reliability of four physical activity measures used in population surveys. *J Sci Med Sport* 2004;7(2):11.
16. Marshall AL, Miller YD, Burton NW, et al. Measuring total and domain-specific sitting: a study of reliability and validity. *Med Sci Sports Exerc* 2010;42(6):9.
17. Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982;5(6):7.
18. Yellen SB, Cella D, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. *J Pain and Symptom Management* 1997;13(2)
19. Peterman AH, Fitchett G, Brady MJ, et al. Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp). *Annals of behavioral medicine : a publication of the Society of Behavioral Medicine* 2002;24(1):49-58. [published Online First: 2002/05/15]
20. Bjelland I, Dahl AA, Haug TT, et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *Journal of psychosomatic research* 2002;52(2):69-77. [published Online First: 2002/02/08]
21. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. *CA Cancer J Clin* 2012;62(4):243-74. doi: 10.3322/caac.21142 [published Online First: 2012/04/28]
22. Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. *Medicine and science in sports and exercise* 2010;42(7):1409-26. doi: 10.1249/MSS.0b013e3181e0c112 [published Online First: 2010/06/19]
23. Groenvold M, Klee MC, Sprangers MAG, et al. Validation of the EORTC QLQ-C30 Quality of Life Questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. *Journal of Clinical Epidemiology* 1997;50(4):441-50.
24. Caudwell P, Gibbons C, Hopkins M, et al. The influence of physical activity on appetite control: an experimental system to understand the relationship between exercise-induced energy expenditure and energy intake. *The Proceedings of the Nutrition Society* 2011;70(2):171-80. doi: 10.1017/S0029665110004751 [published Online First: 2011/01/14]
25. Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, 2009.

## Acknowledgements

We would like to acknowledge our thanks to the following people for their assistance with database design and entry:

Database design: Anne Warby

Data entry: Erika Jungfer and Loraine Fong.

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure Legend

Figure 1 Referral pathway through the Sydney Survivorship Clinic, centre and courses

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-014803 on 9 May 2017. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

**Table 1 Schedule of assessments for patients attending the Sydney Survivorship Clinic or participating in Sydney Survivorship Centre courses:**

a) Sydney Survivorship Clinic

	Assessment	Initial visit	Follow Up*
	Demographics and cancer/ cancer treatment characteristics	X	
	Clinical examination	X	X
	Anthropometry <ul style="list-style-type: none"> <li>• Weight</li> <li>• Weight history</li> </ul>	X X	X
	Blood tests: As per standard of care e.g. colorectal cancer survivors: CEA every 3 months Other blood tests only as clinically indicated	X	X
	Imaging/Procedures: As per ASCO guidelines Breast cancer: Mammogram and/or breast ultrasound annually. Colorectal cancer: CT chest/abdomen/pelvis annually for 5 years. Colonoscopy: 1 year after diagnosis then 1-2 yearly dependent on result  Results of other procedures as ordered by oncology team as part of standard of care.	X	X
Patient Reported Outcomes	Distress (Distress Thermometer) <sup>13</sup>	X	X
	Symptoms (Patient's Disease and Treatment Assessment Form) <sup>12</sup>	X	X
	Sedentary time (Sitting Questionnaire) <sup>16</sup>	X	X*
	Physical activity (Active Australia Questionnaire) <sup>15</sup>	X	X*
	3-day food diary and food questionnaire	X	X*
	Quality of Life questionnaire (FACT-G) <sup>14</sup>	X	X*
	ECOG performance status <sup>17</sup>	X	X
Evaluation	SSC Feedback Questionnaire	X	
	SSC Satisfaction survey		X
	Treatment and Survivorship Plan evaluation		X*

\*Follow up will be individualised depending on tumour type and stage of disease but will generally be every 3-6 months. With the exception of the distress thermometer, Patients Disease and Treatment assessment form and the self-rated performance status, questionnaires will not be completed more frequently than every 6 months.

b) Courses for Sydney Survivorship Centre

Assessment	Initial Visit	Conclusion of Programme
Baseline demographics and disease characteristics	X	
Questionnaires:		
• FACT-G <sup>14</sup>	X	X
• FACT-fatigue (F) subscale <sup>18</sup>	X	X
• FACT Spirituality (Sp) subscale* <sup>19</sup>	X	X
• Patient's Disease and Treatment Assessment Form <sup>12</sup>	X	X
• Distress Thermometer <sup>13</sup>	X	X
• Hospital Anxiety and Depression Scale (HADs) <sup>20</sup>	X	X
Participant evaluation	X	X

\* Only for Medical Qigong, yoga, mindfulness, acupuncture and music and well-being

SSC = Sydney Survivorship Centre

CEA = Carcinoembryonic Antigen; ASCO= American Society of Clinical Oncology;

FACT = Functional Assessment of Cancer Therapy (G= general; F= Fatigue; Sp = spirituality)

**Appendix Table 1 - Schedule of assessments for patients attending the Sydney Survivorship “Weight Management Course”**

Assessment	Baseline	3 Month	6 Month	12 Month
Baseline demographics and disease characteristics, weight history	X			
<b>Clinical examination</b> (accredited exercise physiologist, dietitian, physician)	X	X	X	X
<b>Body Composition</b> Bioimpedance analysis, skinfold measures, girth measures, BMI	X	X		
DEXA scan (where appropriate)	X			X
<b>Fasting blood tests</b> FBC, EUC, LFT, glucose, lipids, iron studies, sex hormones, vitamin D, vitamin B12, TSH, IGF-1, CRP, albumin  Other bloods as appropriate when ordered as standard of care	X	X	X	X
<b>Physical Function</b> 6MWT and/or Graded Sub-maximal Exercise Test; Maximal 1-RM leg press; Hand grip dynamometry	X	X	X	X
<b>Nutritional Status</b> 3-day weighed food diary	X	X	X	X
<b>Patient Reported Outcomes</b> • IPAQ-sf <sup>15</sup> • EORTC-QLQ-C30 <sup>23</sup> • FACT-F 13-item subscale <sup>18</sup> • Patient’s Disease and Treatment Assessment Form <sup>12</sup> • Distress Thermometer <sup>13</sup> • Hunger Visual Analogue Scale <sup>24</sup>	X	X	X	X
<b>Physical Activity Behaviour</b> 7-day Actigraph GT1M accelerometers	X		X	X
Participant program evaluation; semi-structured interviews			X	
Adverse Events (CTCAE V4) <sup>25</sup>		X	X	X

BMI= Body mass index

EORTC-QLQC30 = The European Organisation for Research and Treatment of Cancer

1  
2  
3 FBC = full blood count; EUC = electrolytes, urea, creatinine; LFT = liver function  
4 tests ; TSH = Thyroid stimulating hormone; IGF-1 = Insulin-like growth factor -1;  
5 CRP = C-reactive protein  
6 6MWT= six-minute walk test; 1-RM=one repetition maximum  
7 IPAQ-sf=International Physical Activity Questionnaire – short form  
8 EORTC QLQ-C30= The European Organisation for Research and Treatment of  
9 Cancer Quality of Life Questionnaire  
10 FACT-F = Functional Assessment of Cancer Therapy (F= Fatigue)  
11 CTCAE= common terminology criteria for adverse event  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

For peer review only



1

Figure 1 Referral pathway  
Figure 1 Referral pathway  
254x190mm (96 x 96 DPI)

ew only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### The TIDieR (Template for Intervention Description and Replication) Checklist\*:

Information to include when describing an intervention and the location of the information

Item number	Item	Where located **	
		Primary paper (page or appendix number)	Other † (details)
	<b>BRIEF NAME</b>		
1.	Provide the name or a phrase that describes the intervention.	___ Survivorship Clinic p_5-6, 8-_____ Courses p.6-7	___ Protocol paper_____
	<b>WHY</b>		
2.	Describe any rationale, theory, or goal of the elements essential to the intervention.	p. _4-7__	_____
	<b>WHAT</b>		
3.	Materials: Describe any physical or informational materials used in the intervention, including those provided to participants or used in intervention delivery or in training of intervention providers. Provide information on where the materials can be accessed (e.g. online appendix, URL).	Questionnaires_ p.10__	_____
4.	Procedures: Describe each of the procedures, activities, and/or processes used in the intervention, including any enabling or support activities.	_p. 4-9	_____
	<b>WHO PROVIDED</b>		
5.	For each category of intervention provider (e.g. psychologist, nursing assistant), describe their expertise, background and any specific training given.	p.5-6__	_____
	<b>HOW</b>		
6.	Describe the modes of delivery (e.g. face-to-face or by some other mechanism, such as internet or telephone) of the intervention and whether it was provided individually or in a group.	___p.8__	_____

TIDieR checklist

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

<b>WHERE</b>		
7.	Describe the type(s) of location(s) where the intervention occurred, including any necessary infrastructure or relevant features.	p. 7-8
<b>WHEN and HOW MUCH</b>		
8.	Describe the number of times the intervention was delivered and over what period of time including the number of sessions, their schedule, and their duration, intensity or dose.	_p.7-12_
<b>TAILORING</b>		
9.	If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, and how.	_p.7-12_
<b>MODIFICATIONS</b>		
10.†	If the intervention was modified during the course of the study, describe the changes (what, why, when, and how).	_N/A_
<b>HOW WELL</b>		
11.	Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, describe them.	_N/A_
12.‡	Actual: If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned.	_N/A_

\*\* **Authors** - use N/A if an item is not applicable for the intervention being described. **Reviewers** – use ‘?’ if information about the element is not reported/not sufficiently reported.

† If the information is not provided in the primary paper, give details of where this information is available. This may include locations such as a published protocol or other published papers (provide citation details) or a website (provide the URL).

‡ If completing the TIDieR checklist for a protocol, these items are not relevant to the protocol and cannot be described until the study is complete.

\* We strongly recommend using this checklist in conjunction with the TIDieR guide (see *BMJ* 2014;348:g1687) which contains an explanation and elaboration for each item.

\* The focus of TIDieR is on reporting details of the intervention elements (and where relevant, comparison elements) of a study. Other elements and methodological features of studies are covered by other reporting statements and checklists and have not been duplicated as part of the TIDieR checklist. When a **randomised trial** is being reported, the

TIDieR checklist

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

TIDieR checklist should be used in conjunction with the CONSORT statement (see [www.consort-statement.org](http://www.consort-statement.org)) as an extension of **Item 5 of the CONSORT 2010 Statement**.  
When a **clinical trial protocol** is being reported, the TIDieR checklist should be used in conjunction with the SPIRIT statement as an extension of **Item 11 of the SPIRIT 2013 Statement** (see [www.spirit-statement.org](http://www.spirit-statement.org)). For alternate study designs, TIDieR can be used in conjunction with the appropriate checklist for that study design (see [www.equator-network.org](http://www.equator-network.org)).

For peer review only

TIDieR checklist

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

# BMJ Open

## Health status and needs of cancer survivors attending the Sydney Survivorship Centre clinics and programmes: A protocol of a longitudinal study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014803.R1
Article Type:	Protocol
Date Submitted by the Author:	04-Jan-2017
Complete List of Authors:	Vardy, Janette; University of Sydney, Sydney Medical School; Concord Cancer Centre Tan, Cindy; Concord Repatriation General Hospital, Concord Cancer Centre Turner, Jane; University of Sydney, Centre for Medical Psychology and Evidence-based Medicine Dhillon, Haryana; University of Sydney, Centre for Medical Psychology and Evidence-based Medicine
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Medical management, Nursing, Patient-centred medicine
Keywords:	cancer survivorship, quality of life, survivorship clinic

SCHOLARONE™  
Manuscripts

Health status and needs of cancer survivors attending the Sydney Survivorship Centre  
clinics and programmes: A protocol of a longitudinal study

Janette L. Vardy<sup>1,2,3</sup> Cindy Tan<sup>1</sup>, Jane D Turner<sup>1,3</sup>, Haryana M. Dhillon<sup>3</sup>

<sup>1</sup> Concord Cancer Centre, Concord Hospital, Hospital Rd, Concord, NSW,  
Australia

<sup>2</sup> Sydney Medical School, University of Sydney, Concord Hospital, Hospital  
Rd, Concord, NSW, Australia

<sup>3</sup> Centre for Medical Psychology & Evidence-based Decision-making,  
University of Sydney, NSW, Australia

Janette Vardy [janette.vardy@sydney.edu.au](mailto:janette.vardy@sydney.edu.au)

Cindy Tan [cindy.tan@sswahs.nsw.gov.au](mailto:cindy.tan@sswahs.nsw.gov.au)

Jane Turner [jane.turner@sydney.edu.au](mailto:jane.turner@sydney.edu.au)

Haryana Dhillon [Haryana.dhillon@sydney.edu.au](mailto:Haryana.dhillon@sydney.edu.au)

Corresponding author:

Prof. Janette Vardy MD PhD

Concord Cancer Centre,  
Concord Repatriation General Hospital  
Hospital Rd

Concord, NSW, 2137  
Australia

Phone: +61 2 9767 5000

Fax: +61 2 9767 7934

Email: [janette.vardy@sydney.edu.au](mailto:janette.vardy@sydney.edu.au)



1  
2  
3 Abstract:

4  
5  
6  
7 Introduction:

8  
9  
10 The care of cancer survivors after primary adjuvant treatment is recognised as a  
11 distinct phase of the cancer journey. Recent research highlights the importance of  
12 lifestyle factors in treating symptoms, potentially decreasing risk of a cancer  
13 recurrence, and modifying the risk of developing other chronic illnesses that are  
14 increased in the cancer population. Survivorship services aim to deliver care that  
15 addresses these issues. The overall aims are to determine the health status of cancer  
16 survivors and evaluate the services offered by the Sydney Survivorship Centre.  
17  
18  
19  
20  
21  
22  
23  
24

25 Methods and analysis:

26  
27 An observational, single centre study evaluating the longitudinal physical and  
28 psychological health, symptoms, quality of life, and lifestyle (physical activity and  
29 nutrition) of early-stage cancer survivors attending the multidisciplinary Sydney  
30 Survivorship Clinic and of survivors (at any stage of the cancer journey) and  
31 caregivers participating in Sydney Survivorship Centre courses. Evaluation of patient  
32 satisfaction is included. Patient reported outcomes and patient characteristics will be  
33 summarised using descriptive statistics with Spearman rank sum correlation  
34 coefficients to determine associations between patient-reported outcomes. Regression  
35 modelling may be used to further evaluate associations and to investigate risk factors  
36 and predictors of health outcomes. Qualitative data will be analysed using thematic  
37 analysis to identify themes. Sample size will be determined by attendance of  
38 consenting patients at clinics and courses.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 Ethics and dissemination:  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The study has received ethics approval from the Concord Repatriation General  
4 Hospital Human Research Ethics Committee (HREC/14/CRGH/23). The results will  
5  
6  
7 be published and presented at appropriate conferences.  
8

9  
10 This study will provide important information regarding the health status and needs of  
11 Australian cancer survivors, and the ability of the Survivorship Centre to address  
12 these needs. These data will shape the future direction of survivorship care in  
13 Australia and facilitate the design of interventions or measures to provide better  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

quality of care to this patient population.

## Introduction

Until relatively recently the focus of cancer treatment and research was on the acute treatment of cancer and monitoring for disease recurrence. In 2005 the groundbreaking Institute of Medicine (IOM) Report “Lost in Transition” identified the substantial failure of current follow-up care to comprehensively address the needs of adult cancer survivors.<sup>1</sup> Through the IOM the distinct needs of adult cancer survivors have been recognised along with the importance of helping survivors live with the longer term physical, psychological, and practical effects of cancer and its treatment.<sup>1</sup>

By the broadest definition a person becomes a cancer survivor when they are diagnosed with cancer, a state that continues throughout the remainder of their life.<sup>1</sup>

There are estimated to be more than 25 million cancer survivors worldwide, a number that is projected to increase rapidly due to our ageing population, improved screening leading to earlier detection of cancer, and improvements in cancer treatments.

Even cancer survivors with no evidence of disease recurrence experience greater ongoing health problems than the general population. Cancer survivors are known to be at increased risk of cardiovascular disease, type II diabetes, metabolic syndrome, and osteoporosis, in addition to the risk of a cancer recurrence or a second primary cancer.<sup>1-5</sup> There are a number of identified lifestyle risk factors associated with cancer risk and recurrence, and the chronic diseases that accompany them. These lifestyle risk factors are modifiable and include obesity, physical inactivity, smoking, and inadequate fruit and vegetable intake.<sup>6</sup>

In an attempt to better address the needs of adult cancer survivors some cancer centres have established Survivorship Services, Centres, or Clinics. These services are

1  
2  
3 designed to help survivors and their caregivers better manage their disease and any  
4 lasting effects of treatment, beyond the period of acute diagnosis and treatment.<sup>5</sup> In  
5  
6  
7 addition, many try to facilitate survivors enacting lifestyle changes to increase their  
8  
9  
10 physical activity and maintain a healthy weight, in order to aid recovery, improve  
11  
12 health related quality of life (QOL), and possibly long-term survival.<sup>7</sup> Psychological  
13  
14 support is an important feature of most programmes, and may include psycho-  
15  
16 oncology consultations with a clinical psychologist to manage specific concerns such  
17  
18 as fear of cancer recurrence, anxiety, or depression, general or disease specific  
19  
20 support groups, or counselling support from allied health professionals.<sup>8,9</sup>

21  
22  
23 The IOM recommended, with support of a number of peak bodies including the  
24  
25 American Society of Clinical Oncology (ASCO), that all cancer survivors  
26  
27 transitioning from active to the post treatment phase should receive an individualised  
28  
29 Treatment and Survivorship Care Plan (SCP).<sup>1</sup> This should include a summary of  
30  
31 cancer treatment received, and recommendations regarding future clinical care and  
32  
33 coordination, including the frequency and nature of surveillance based on the best  
34  
35 available evidence. A number of SCP templates are freely available, including generic  
36  
37 and disease specific templates from ASCO and Livestrong, which include information  
38  
39 on potential late and long-term effects from the cancer and/or treatment(s). Despite  
40  
41 recommendations from oncology organisations that SCP should be used, there is  
42  
43 limited evidence that they improve long term outcomes for cancer survivors although  
44  
45 survivor satisfaction with the SCP is generally high.<sup>10</sup>

46  
47  
48  
49 The Sydney Survivorship Centre was established in September 2013 at the Concord  
50  
51 Cancer Centre, in Sydney. It includes: i) a multi-disciplinary survivorship clinic for  
52  
53 patients with localised cancer who have completed primary treatment with curative  
54  
55 intent (e.g. surgery, chemotherapy, and radiation therapy) without evidence of cancer  
56  
57  
58  
59  
60

1  
2  
3 recurrence; and, ii) a range of programmes to support lifestyle change. At the initial  
4 clinic visit patients see a multi-disciplinary team (MDT) comprising a medical  
5 oncologist or haematologist, cancer nurse specialist, dietitian, clinical psychologist,  
6 and accredited exercise physiologist (AEP). Prior to attendance at each clinic,  
7 patients complete a number of questionnaires assessing symptoms, physical activity,  
8 diet, QOL and well-being, and are asked to fill in an evaluation after each clinic.  
9 Education regarding healthy lifestyle and encouragement to maintain a healthy weight  
10 are an important focus of every clinic. An individualised SCP is developed for each  
11 oncology patient.

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23 Approximately two thirds of survivors attend the clinic once and then return to their  
24 regular medical team for ongoing follow up. At the request of the caring team, the  
25 remainder continue follow up through the Survivorship Clinic. On subsequent visits  
26 they see the medical oncologist and tumour specific nurse specialist, with referral to  
27 other health professionals and/or programmes as required.

28  
29  
30  
31  
32  
33  
34 In response to the high proportion of survivors who were overweight or obese, and the  
35 increasing evidence supporting obesity as a risk factor for cancer recurrence,<sup>11</sup> we  
36 established a weight management clinic focused on dietary modification, exercise and  
37 behavioural change for those with early stage solid tumours, who have a body mass  
38 index (BMI) >25. The intervention was based on a recent systematic review that  
39 reported dietary modification involving restrictions of energy and fat intake, and  
40 promotion of exercise and behavioural changes were the key components for  
41 successful weight loss and maintenance.<sup>12</sup>

42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54 The Sydney Survivorship Centre opened the Survivorship Cottage in May 2014. The  
55 cottage is located in the grounds of the hospital, away from the main buildings, and  
56  
57  
58  
59  
60

1  
2  
3 surrounded by gardens and furnished in a homely manner. This is where the majority  
4  
5 of the courses are held for cancer survivors at any stage of their cancer journey, and  
6  
7 their caregivers, with a focus on healthy lifestyle and well-being. The Exercise and  
8  
9 Nutrition Routine Improving Cancer Health (ENRICH)<sup>13</sup> programme is a 6-week  
10  
11 exercise and healthy eating course offered in collaboration with the Cancer Council  
12  
13 New South Wales (NSW) and held regularly throughout the year. Other courses  
14  
15 include: Mindfulness Meditation, Medical QiGong, yoga, acupuncture, music and art  
16  
17 therapy, including scrap-booking, card making, floral design as well as individual  
18  
19 one-off workshops. Courses are selected based on some level of evidence for their  
20  
21 efficacy in cancer survivors.<sup>14-20</sup> The courses are offered weekly for 10 weeks  
22  
23 coinciding with school terms, with 4 terms each year. Commitment to a full term is  
24  
25 required. In addition we provide support groups and public fora on topics of interest  
26  
27 to cancer patients and their caregivers and families.  
28  
29  
30  
31

32  
33 In keeping with the ASCO guidelines,<sup>5</sup> research is an integral component of the  
34  
35 Survivorship Centre. The major research aims of the centre are to: (i) determine the  
36  
37 health status, needs, symptoms, QOL and lifestyle characteristics of cancer survivors  
38  
39 attending the Sydney Survivorship Clinic or participating in courses; (ii) evaluate  
40  
41 changes over time in these variables; (iii) determine risk factors that may affect cancer  
42  
43 survivors' clinical outcomes (e.g. metabolic syndrome, obesity, inactivity); (iv)  
44  
45 evaluate patients' and/or their caregivers/family members' experience with services  
46  
47 offered by the Sydney Survivorship Centre; and (v) evaluate the multidisciplinary  
48  
49 team (MDT) approach in addressing cancer survivors' needs.  
50  
51  
52  
53  
54

## 55 Methods and Analysis

56  
57 This is a single site, longitudinal study led by the Survivorship Research Group  
58  
59  
60

1  
2  
3 (SuRG), University of Sydney and the Sydney Survivorship Centre, Concord Cancer  
4 Centre. Patient reported outcome data are collected as part of standard care and for  
5 quality assurance.  
6  
7  
8  
9

10  
11 *Sydney Survivorship Clinic:*

12 The Sydney Survivorship Centre (SSC) clinic commenced in September 2013.  
13  
14

15  
16  
17 Eligibility:

18  
19 Medical oncology or haematology patients who have completed primary adjuvant  
20 treatment for early stage cancer and have no evidence of a cancer recurrence are  
21 eligible to attend the Survivorship Clinic. Breast cancer patients may be receiving  
22 hormonal treatment and/or targeted therapy such as trastuzumab. Figure 1 depicts the  
23 referral pathway.  
24  
25  
26  
27  
28  
29

30  
31 Procedure:

32  
33 Prior to attending the Survivorship clinic patients are sent a package containing  
34 printed Patient Reported Outcome (PRO) Questionnaires assessing symptoms,  
35 psychological well-being, distress, QOL, physical activity, dietary intake and  
36 performance status. They are asked to bring the completed questionnaires to their  
37 appointment. Those with incomplete questionnaires are asked to finalise them during  
38 the clinic visit. Patients with insufficient English or poor literacy skills can have  
39 assistance from a health translator, family members, or clinic staff during the clinic  
40 appointment.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52 Medical information and weight history are obtained from the medical record.  
53

54 Anthropometry (height and weight) is obtained at the initial visit by clinic staff. A  
55  
56  
57  
58  
59  
60

1  
2  
3 SCP is prepared for oncology patients prior to their initial visit, by either the medical  
4 oncologist or registrar. This plan is refined with the patient after consultation with the  
5 MDT members, and a copy posted to them after the clinic. Haematology patients may  
6 receive a detailed letter from the haematologist with recommendations rather than a  
7 formal Survivorship care plan.  
8  
9

10  
11  
12  
13  
14  
15  
16 Patients are asked to complete an evaluation form after each clinic visit. In addition,  
17 those who have given verbal permission to be contacted subsequently will be asked to  
18 complete a satisfaction survey over the phone or in person to provide feedback on  
19 how useful the Survivorship Care Plan has been, how they used it, and if it has been  
20 revised. This will be approximately 6 months after their initial visit. A subset of  
21 patients will be invited to participate in a qualitative interview to explore, in depth,  
22 their experience of the survivorship service.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

### 33 34 *Sydney Survivorship Courses:*

35  
36 The courses were gradually introduced from 2014.

### 37 38 Eligibility:

39  
40 Posters advertising the programmes are displayed in the Concord Cancer Centre  
41 waiting areas. Patients with any stage cancer are able to self-refer to participate in  
42 Survivorship courses. Concord Cancer Centre patients receive priority for courses, but  
43 patients from surrounding hospitals are able to attend if space permits. Carers can  
44 accompany a patient and participate if space permits.  
45  
46  
47  
48  
49  
50

### 51 52 Measures used for Survivorship Clinic and Courses:



1  
2  
3 Outcome measures used in this study are comprehensive assessments of patient self-  
4 report symptoms, QOL, distress, and lifestyle factors. The schedule of assessments  
5 and details of measures are outlined in Table 1.  
6  
7  
8

9  
10  
11 Endpoints:

12  
13  
14 The global aim of this multi-faceted project is to evaluate the Sydney Survivorship  
15 Centre Clinic and Programmes. We aim to assess changes in the endpoints, stated  
16 below, over time:  
17  
18  
19

20  
21  
22 *Survivorship Clinic*

- 23  
24 • incidence and severity of symptoms that may be associated with cancer and/or  
25 treatment – as assessed by the Patient’s Disease and Treatment Assessment  
26 Form.<sup>21</sup> This is a 48 item questionnaire assessing symptoms with responses  
27 ranging from 0 – 10 (no trouble at all to worst I can imagine) over the  
28 previous month.  
29  
30 • distress - as assessed by the Distress thermometer.<sup>22</sup> This asks participants to  
31 rate their level of distress over the previous week from 0 – 10 (no distress to  
32 extreme distress).  
33  
34 • quality of life as assessed by the FACT-G.<sup>23</sup> This 27-item questionnaire  
35 assesses physical, social, emotional and functional well-being over the  
36 previous week, with ratings from 0 – 4 (not at all to very much).  
37  
38 • physical activity and sedentary behaviour- as assessed by the Active Australia  
39 Exercise Questionnaire<sup>24</sup> and the Sitting Questionnaire<sup>25</sup> and AEP  
40 consultation. Active Australia is a 4-item questionnaire evaluating the time  
41 spent performing physical activity and the intensity of the activity in the  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 previous week. The Sitting questionnaire is a 2-item questionnaire assessing  
4 the time usually spent sitting, on a weekday and on a weekend.  
5  
6

- 7  
8 • dietary intake and behaviour – as assessed by an in-house 3-day food diary  
9 and Food Questionnaire, and dietitian consultation. The 4-item Food  
10 Questionnaire assesses changes made to diet since a cancer  
11 diagnosis/treatment, average number of serves of fruit, vegetables, dairy and  
12 soft drinks daily, and alcohol intake.  
13  
14 • Eastern Co-operative Oncology Group Performance Status (ECOG  
15 Performance Status)<sup>26</sup> - as assessed by both clinician and participant.  
16  
17 • Clinical assessments: medical and physical assessment by doctor and nurse;  
18 fear of cancer recurrence assessed by Clinical Psychologist, anthropometric  
19 assessment.  
20  
21 • Effectiveness of MDT in addressing survivors' needs measured by change in  
22 outcomes, e.g., QOL, sedentary behaviour, etc  
23  
24 • Use and effectiveness of Treatment and Survivorship Care Plan (SCP). To  
25 determine the incidence of patients attending the Survivorship Clinic who:  
26 receive a survivorship plan; are referred to other health professionals from  
27 clinic; use the SCP (e.g. show other health professionals, carry out the clinic  
28 recommendations). Whether patients found the SCP helpful, did it contain  
29 new information and suggestions for improvement.  
30  
31 • Clinical progress as determined by results of clinical examination, blood tests  
32 and/or imaging ordered as part of standard of care.  
33  
34 • Effectiveness of surveillance system: Total number of cases of cancer  
35 recurrence and disease-free survival.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 • Patients' experience with Sydney Survivorship Clinic, developed by the  
4 authors, asking patients to rate how useful the session with each member of  
5 the multidisciplinary team was, and how well their questions were answered.  
6  
7 They also rate how worthwhile it was attending the clinic and give reasons for  
8 their answer, and comment on the length and timing of the clinic in their  
9 cancer journey. Finally they are asked whether they would recommend the  
10 clinic to others and any additional information or services they would have  
11 liked to receive.  
12  
13  
14  
15  
16  
17  
18  
19

20  
21 *Specific SSC programmes:*

22  
23 Weight management programme:

- 24  
25 • Facilitated and supervised by AEP and Dietitian.  
26  
27 • Eligibility: BMI >25; attendance at Sydney Survivorship Clinic, completion of  
28 the ENRICH 6 week lifestyle programme.  
29  
30 • attendance (number of enrolees, proportion completing programmes, reasons  
31 for non-attendance).  
32  
33 • QOL, symptoms, food intake, exercise behaviour, knowledge/practice and  
34 changes compared to baseline assessment.  
35  
36 • Lifestyle outcomes: anthropometry measurements, vital signs, aerobic capacity  
37 and muscular strength - Week 0, 12, 26 and then 6 monthly until 2 years.  
38  
39 • blood results collected as part of standard of care.  
40  
41 • patient experience as measured by a satisfaction survey and interview.  
42  
43  
44  
45  
46  
47  
48

49 See Appendix Table 1 for full details.

50  
51 Mindfulness, QiGong, Yoga, Music therapy, Art therapy or similar courses:

- 52  
53 • Attendance (number of enrolees, proportion completing programmes, reasons  
54 for non-attendance)  
55  
56  
57  
58  
59  
60

- Clinical outcomes: demographics, cancer diagnosis and treatment,
- Symptoms: assessed by the Patient's Disease and Treatment Assessment Form<sup>21</sup>
- Psychosocial outcomes (completed pre and post intervention):
  - QOL and fatigue assessed by the FACT-General (G)<sup>23</sup> and 13-item Fatigue (F) subscale<sup>27</sup>
  - Spiritual well-being assessed by the 12-item FACT-Spiritual<sup>28</sup> (for mindfulness, yoga medical Qigong, acupuncture and medical well-being courses)
  - Symptoms of anxiety and depression –assessed by the Hospital Anxiety and Depression Scale (HADS)<sup>29</sup>
  - Distress – assessed by the Distress Thermometer<sup>22</sup>
- ECOG performance status (patient rated)<sup>26</sup>
- Participant satisfaction questionnaire – at end of programme only

In-depth Qualitative exploration of patient experience:

Cancer survivors and/or caregivers/family members will be invited to participate in focus group(s) and/or interviews to provide in-depth feedback about their experience of SSC services, and information about unmet needs to guide the direction of the SSC clinic or programmes. Both focus groups and telephone interviews are offered to ensure maximum access for individual participants via these flexible options. Consenting individuals will attend a focus group meeting, a face-to-face interview, or a telephone interview with staff of the University of Sydney who are not involved in their clinical care. All interviews are semi-structured, following an ethics approved interview guide developed for the clinic and each programme.

To monitor changing experiences of the clinic over time, groups of attendees will be purposively sampled periodically on the basis of their disease group, side effect profile, and the programmes attended.

Qualitative data will be transcribed verbatim and analysed using thematic analysis.

#### Data analysis and statistical issues

This protocol describes a data collection process that is ongoing as part of service evaluation. The sample included in each analysis will be dependent on the specific questions asked, with specific hypotheses developed prior to analyses, and the sample size determined for each proposed analysis. The sample size will be determined by attendance of consenting patients at clinics and courses. It is estimated that the Survivorship clinic will see 100 new patients per year, of whom 90% will consent to the use of their de-identified data. The first evaluation of initial clinic visits will be performed after 3 years, with an estimated sample size of 300 new patients. This would be considered of clinical significance for determining health status, Approximately 25% of the medical oncology patients receive their follow up at the Survivorship Clinic. We will perform a longitudinal analysis once we have three year follow up for 150 patients. Three year disease free survival is considered a surrogate marker for overall survival for some common tumour types,<sup>30</sup> and this time frame would provide important information on longitudinal health status of survivors.

Outcomes and patient characteristics will be summarised using standard descriptive statistics for each group. Missing data on the PRO will be handled according to the guidelines for each questionnaire. Comparison of results between groups (for example comparing PRO between tumour types) will be performed using Kruskal-Wallis test for continuous variables, Cochran-Armitage test for trend for ordinal variables, and

1  
2  
3 exact  $\chi^2$  tests for categorical variables. Spearman rank sum correlation coefficients  
4  
5 will be used to determine associations between patient-reported outcomes.  
6  
7 Regression modelling may be used to further evaluate associations and to investigate  
8  
9 risk factors and predictors of health outcomes.  
10

11 For longitudinal changes in patient reported outcomes a 10% change in the scale from  
12  
13 baseline will be considered a clinically meaningful change.<sup>31</sup> A comparison of change  
14  
15 over time in symptoms and behaviours will be performed. Changes in PRO at each  
16  
17 time point will be analysed and regression analyses may be subsequently performed  
18  
19 for major health status outcomes, to adjust for variables such as time since treatment  
20  
21 completion and tumour site.  
22

23 Qualitative data analysis: Interview data will be analysed using thematic analysis with  
24  
25 at least two people involved in the analysis. Data coding will occur within a  
26  
27 framework using MS office Excel.<sup>32</sup> Rigour will be ensured through multiple  
28  
29 readings of the data, multiple coders, cross-coding, and member checking of  
30  
31 themes with attendees of the clinic.  
32  
33  
34  
35  
36  
37  
38

### 39 **Discussion:**

40 Survivorship concerns are increasingly recognised as poorly addressed in many  
41  
42 standard follow-up appointments. There is considerable debate and a lack of evidence  
43  
44 regarding how best to follow up cancer survivors. Multi-disciplinary clinics have the  
45  
46 capacity to provide holistic care with a focus on education for lifestyle issues,  
47  
48 prevention of long term side effects and psychological well being; but they are  
49  
50 resource intensive for staff.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 A physically active lifestyle and healthy weight have been shown in observational  
4 studies to decrease the risk of common cancers and cancer recurrence. Studies have  
5 also shown that physical activity and healthy nutrition can improve symptoms  
6 associated with cancer treatment, and decrease the risk of chronic diseases that are  
7 commonly found in cancer survivors; including metabolic syndrome, obesity, type II  
8 diabetes, cardiovascular disease and osteoporosis.<sup>33</sup> Although a number of cancer  
9 organisations have published recommendations regarding exercise and weight, the  
10 majority of cancer patients are overweight or obese, and most do not meet the  
11 guidelines of 150 minutes/week of moderate intensity physical activity, two sessions  
12 of resistance exercise/week and minimising sedentary activities, despite the increasing  
13 evidence for benefit.<sup>33 34</sup> This suggests that cancer survivors require additional  
14 support and education to facilitate their instituting important lifestyle changes.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 The Sydney Survivorship Centre has the potential to improve physical and  
30 psychological well-being and QOL for cancer survivors. This study will obtain unique  
31 data regarding the benefits of a multi-disciplinary team Survivorship clinic for cancer  
32 patients who have completed primary adjuvant treatment, and evaluation of the  
33 courses offered by the Sydney Survivorship Centre for patients at any stage of the  
34 cancer journey and their caregivers/family. This will help determine whether  
35 assessing health status, providing education and lifestyle programmes facilitates  
36 adoption and adherence to a healthy lifestyle, and whether this can lead to  
37 improvement in well-being. Further, it will evaluate the Survivorship care plans  
38 through usage in routine clinical practice, as well as gaining information about who  
39 uses the Sydney Survivorship Centre programmes, and patient (and caregiver)  
40 satisfaction with the clinic and courses.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The strengths of the study are that it will provide a large sample size with longitudinal  
4 follow up with comprehensive assessment of health and well-being of cancer  
5 survivors attending a multi-disciplinary Survivorship Centre post primary adjuvant  
6 treatment. Limitations of the study include that it is an uncontrolled, observational  
7 cohort study, with the sample size dependent on the number of patients attending the  
8 clinic and programmes who consent to their deidentified data being used.  
9  
10  
11  
12  
13  
14  
15  
16  
17

#### 18 Ethics Approval:

19  
20  
21 Ethics approval has been obtained from Concord Repatriation General Hospital  
22 Human Research Ethics Committee (HREC/14/CRGH/23). Patients attending clinics  
23 and courses at the Sydney Survivorship Centre are given the option of a tick box to  
24 “opt out” if they do not wish their de-identified data to be used for research purposes.  
25  
26  
27  
28  
29  
30

#### 31 Dissemination Plan:

32  
33  
34 Study results will be disseminated through a series of peer-reviewed publications and  
35 conference presentations.  
36  
37  
38  
39

#### 40 Data storage and security:

41  
42  
43 Questionnaires are part of standard medical care and are kept in patient’s oncology  
44 subfile. Data are entered into a specifically designed REDCap<sup>TM</sup> database, that is  
45 password protected and kept on a secure University of Sydney website. Records are  
46 identified by a study ID number, and a master list with names is kept separately. Data  
47 can only be accessed by authorised research team members. Data will be retained in  
48 perpetuity after conclusion of the study, and after each patient is discharged from the  
49 Survivorship Service either through completion of follow-up, disease recurrence, or  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 death their data will be fully anonymised by destruction of their details from the  
4  
5 master list.  
6

7  
8 Conclusions:

9  
10 Survivorship services are expanding in Australia and globally. The Sydney  
11  
12 Survivorship Centre is the only multidisciplinary clinic of its kind in Australia. This  
13  
14 study will provide important information about the health status of Australian cancer  
15  
16 survivors, and enable us to better understand the symptoms, lifestyle and risk factors  
17  
18 of our patient population. This will facilitate the design of supportive measures or  
19  
20 interventions to better address these issues.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Author Contributions:

4  
5 J. Vardy: study concept and design, and writing of the protocol and manuscript.  
6 C. Tan: study concept and design, and writing of the protocol and manuscript.  
7 J. Turner: study concept and design, and writing of the protocol and manuscript.  
8 H. Dhillon: study concept and design, and writing of the protocol and manuscript.  
9

10  
11 Competing Interests:

12 None of the authors have any conflicts of interest to declare.  
13

14 Funding Statement:

15  
16 This research is supported by a grant from the National Breast Cancer Foundation,  
17 Australia, in the form of a Practitioner Fellowship to Prof. Janette Vardy. (PRAC-15-  
18 003).  
19

20  
21 Data Sharing:

22 This is a protocol for a longitudinal study so unpublished data are not available for  
23 sharing.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Hewitt ME, Ganz PA, Institute of Medicine (U.S.), et al. From cancer patient to cancer survivor : lost in transition : an American Society of Clinical Oncology and Institute of Medicine Symposium. Washington, D.C.: National Academies Press 2006.
2. Baade P, Fritschi L, Eakin E. Non-cancer mortality among people diagnosed with cancer (Australia). *Cancer Causes and Control* 2006;17:287-97.
3. Holmes MD, Chen WY, Feskanich D, et al. Physical activity and survival after breast cancer diagnosis. *JAMA* 2005;293(20):2479-86. doi: 10.1001/jama.293.20.2479
4. Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical Activity and Survival After Colorectal Cancer Diagnosis. *J Clin Oncol* 2006;24(22):3527-34. doi: 10.1200/jco.2006.06.0855
5. McCabe MS, Bhatia S, Oeffinger KC, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31(5):631-40. doi: 10.1200/JCO.2012.46.6854 [published Online First: 2013/01/09]
6. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington DC: World Cancer Research Fund/American Institute Cancer Research, 2007.
7. Hewitt ME, Greenfield S, Stovall E, et al. From cancer patient to cancer survivor : lost in transition. Washington, D.C.: National Academies Press 2006.
8. Jacobsen PB. Clinical practice guidelines for the psychosocial care of cancer survivors: current status and future prospects. *Cancer* 2009;115(18 Suppl):4419-29. doi: 10.1002/cncr.24589 [published Online First: 2009/09/05]
9. Clinical guidance for responding to suffering in adults with cancer Sydney: Cancer Australia; 2014 [updated June 2014; cited 2016 20th December 2016]. Clinical Guidelines]. accessed December 2016 2016.
10. Kinnane N, Moore, R., Jefford, M., Piper, A., Nolte, L. Survivorship care plans: literature review. Melbourne: Australian Cancer Survivorship Centre, Peter MacCallum, Cancer Centre, 2015.
11. Demark-Wahnefried W, Platz EA, Ligibel JA, et al. The role of obesity in cancer survival and recurrence. *Cancer Epidemiology Biomarkers & Prevention* 2012;21(8):1244-59. doi: 10.1158/1055-9965.epi-12-0485
12. Ramage S, Farmer A, Apps Eccles K, et al. Healthy strategies for successful weight loss and weight maintenance: a systematic review. *Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme* 2014;39(1):1-20. doi: 10.1139/apnm-2013-0026 [published Online First: 2014/01/05]
13. James EL, Stacey FG, Chapman K, et al. Impact of a nutrition and physical activity intervention (ENRICH: Exercise and Nutrition Routine Improving Cancer Health) on health behaviors of cancer survivors and carers: a pragmatic randomized controlled trial. *BMC cancer* 2015;15 doi: 10.1186/s12885-015-1775-y
14. Buffart LM, van Uffelen JG, Riphagen, II, et al. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. *BMC cancer* 2012;12:559. doi: 10.1186/1471-2407-12-559 [published Online First: 2012/11/28]

15. Lengacher CA, Reich RR, Paterson CL, et al. Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2016;34(24):2827-34. doi: 10.1200/JCO.2015.65.7874 [published Online First: 2016/06/02]
16. Tao WW, Jiang H, Tao XM, et al. Effects of Acupuncture, Tuina, Tai Chi, Qigong, and Traditional Chinese Medicine Five-Element Music Therapy on Symptom Management and Quality of Life for Cancer Patients: A Meta-Analysis. *Journal of pain and symptom management* 2016;51(4):728-47. doi: 10.1016/j.jpainsymman.2015.11.027 [published Online First: 2016/02/18]
17. Zhou K, Li X, Li J, et al. A clinical randomized controlled trial of music therapy and progressive muscle relaxation training in female breast cancer patients after radical mastectomy: results on depression, anxiety and length of hospital stay. *European journal of oncology nursing : the official journal of European Oncology Nursing Society* 2015;19(1):54-9. doi: 10.1016/j.ejon.2014.07.010 [published Online First: 2014/09/04]
18. Chiu HY, Shyu YK, Chang PC, et al. Effects of Acupuncture on Menopause-Related Symptoms in Breast Cancer Survivors: A Meta-analysis of Randomized Controlled Trials. *Cancer nursing* 2016;39(3):228-37. doi: 10.1097/NCC.0000000000000278 [published Online First: 2015/06/08]
19. Oh B, Butow P, Mullan B, et al. Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2010;21(3):608-14. doi: 10.1093/annonc/mdp479 [published Online First: 2009/11/03]
20. Wood MJ, Molassiotis A, Payne S. What research evidence is there for the use of art therapy in the management of symptoms in adults with cancer? A systematic review. *Psycho-oncology* 2011;20(2):135-45. doi: 10.1002/pon.1722 [published Online First: 2010/09/30]
21. Stockler MR, O'Connell R, Nowak AK, et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. *The lancet oncology* 2007;8(7):603-12. doi: 10.1016/S1470-2045(07)70148-1
22. Tuinman MA, Gazendam-Donofrio SM, Hoekstra-Weebers JE. Screening and referral for psychosocial distress in oncologic practice: use of the Distress Thermometer. *Cancer* 2008;113(4):870-8. doi: 10.1002/cncr.23622 [published Online First: 2008/07/12]
23. Cella D, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. *J Clin Oncol* 1993;11(3):10.
24. Brown WJ, Trost SG, Bauman A, et al. Test-retest reliability of four physical activity measures used in population surveys. *J Sci Med Sport* 2004;7(2):11.
25. Marshall AL, Miller YD, Burton NW, et al. Measuring total and domain-specific sitting: a study of reliability and validity. *Med Sci Sports Exerc* 2010;42(6):9.
26. Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982;5(6):7.
27. Yellen SB, Cella D, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. *J Pain and Symptom Management* 1997;13(2)

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
28. Peterman AH, Fitchett G, Brady MJ, et al. Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp). *Annals of behavioral medicine : a publication of the Society of Behavioral Medicine* 2002;24(1):49-58. [published Online First: 2002/05/15]
  29. Bjelland I, Dahl AA, Haug TT, et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *Journal of psychosomatic research* 2002;52(2):69-77. [published Online First: 2002/02/08]
  30. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2005;23(34):8664-70. doi: 10.1200/JCO.2005.01.6071
  31. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. *J Clin Oncol* 1998;16(1):139-44.
  32. Pope C, Ziebland S, Mays N. Qualitative research in health care. Analysing qualitative data. *BMJ* 2000;320(7227):114-6.
  33. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. *CA Cancer J Clin* 2012;62(4):243-74. doi: 10.3322/caac.21142 [published Online First: 2012/04/28]
  34. Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. *Medicine and science in sports and exercise* 2010;42(7):1409-26. doi: 10.1249/MSS.0b013e3181e0c112 [published Online First: 2010/06/19]
  35. Groenvold M, Klee MC, Sprangers MAG, et al. Validation of the EORTC QLQ-C30 Quality of Life Questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. *Journal of Clinical Epidemiology* 1997;50(4):441-50.
  36. Caudwell P, Gibbons C, Hopkins M, et al. The influence of physical activity on appetite control: an experimental system to understand the relationship between exercise-induced energy expenditure and energy intake. *The Proceedings of the Nutrition Society* 2011;70(2):171-80. doi: 10.1017/S0029665110004751 [published Online First: 2011/01/14]
  37. Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, 2009.

## Acknowledgements

We would like to acknowledge our thanks to the following people for their assistance with database design and entry:

Database design: Anne Warby

Data entry: Erika Jungfer, Loraine Fong and Christopher Mo.

For peer review only

1  
2  
3 Figure Legend  
4

5 Figure 1 Referral pathway through the Sydney Survivorship Clinic, centre and  
6 courses  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



**Table 1 Schedule of assessments for patients attending the Sydney Survivorship Clinic or participating in Sydney Survivorship Centre courses:**

a) Sydney Survivorship Clinic

	Assessment	Initial visit	Follow Up*
	Demographics and cancer/ cancer treatment characteristics	X	
	Clinical examination	X	X
	Anthropometry <ul style="list-style-type: none"> <li>• Weight</li> <li>• Weight history</li> </ul>	X X	X
	Blood tests: As per standard of care e.g. colorectal cancer survivors: CEA every 3 months Other blood tests only as clinically indicated	X	X
	Imaging/Procedures: As per ASCO guidelines Breast cancer: Mammogram and/or breast ultrasound annually. Colorectal cancer: CT chest/abdomen/pelvis annually for 5 years. Colonoscopy: 1 year after diagnosis then 1-2 yearly dependent on result  Results of other procedures as ordered by oncology team as part of standard of care.	X	X
Patient Reported Outcomes	Distress (Distress Thermometer) <sup>22</sup>	X	X
	Symptoms (Patient's Disease and Treatment Assessment Form) <sup>21</sup>	X	X
	Sedentary time (Sitting Questionnaire) <sup>25</sup>	X	X*
	Physical activity (Active Australia Questionnaire) <sup>24</sup>	X	X*
	3-day food diary and food questionnaire	X	X*
	Quality of Life questionnaire (FACT-G) <sup>23</sup>	X	X*
	ECOG performance status <sup>26</sup>	X	X
Evaluation	SSC Feedback Questionnaire	X	
	SSC Satisfaction survey		X
	Treatment and Survivorship Plan evaluation		X*



\*Follow up will be individualised depending on tumour type and stage of disease but will generally be every 3-6 months. With the exception of the distress thermometer, Patients Disease and Treatment assessment form and the self-rated performance status, questionnaires will not be completed more frequently than every 6 months.

b) Courses for Sydney Survivorship Centre

Assessment	Initial Visit	Conclusion of Programme
Baseline demographics and disease characteristics	X	
Questionnaires:		
• FACT-G <sup>23</sup>	X	X
• FACT-fatigue (F) subscale <sup>27</sup>	X	X
• FACT Spirituality (Sp) subscale* <sup>28</sup>	X	X
• Patient's Disease and Treatment Assessment Form <sup>21</sup>	X	X
• Distress Thermometer <sup>22</sup>	X	X
• Hospital Anxiety and Depression Scale (HADs) <sup>29</sup>	X	X
Participant evaluation	X	X

\* Only for Medical Qigong, yoga, mindfulness, acupuncture and music and well-being

SSC = Sydney Survivorship Centre

CEA = Carcinoembryonic Antigen; ASCO= American Society of Clinical Oncology;

FACT = Functional Assessment of Cancer Therapy (G= general; F= Fatigue; Sp = spirituality)

**Appendix Table 1 - Schedule of assessments for patients attending the Sydney Survivorship “Weight Management Course”**

Assessment	Baseline	3 Month	6 Month	12 Month
Baseline demographics and disease characteristics, weight history	X			
<b>Clinical examination</b> (accredited exercise physiologist, dietitian, physician)	X	X	X	X
<b>Body Composition</b> Bioimpedance analysis, skinfold measures, girth measures, BMI	X	X		
DEXA scan (where appropriate)	X			X
<b>Fasting blood tests</b> FBC, EUC, LFT, glucose, lipids, iron studies, sex hormones, vitamin D, vitamin B12, TSH, IGF-1, CRP, albumin  Other bloods as appropriate when ordered as standard of care	X	X	X	X
<b>Physical Function</b> 6MWT and/or Graded Sub-maximal Exercise Test; Maximal 1-RM leg press; Hand grip dynamometry	X	X	X	X
<b>Nutritional Status</b> 3-day weighed food diary	X	X	X	X
<b>Patient Reported Outcomes</b> • IPAQ-sf <sup>24</sup> • EORTC-QLQ-C30 <sup>35</sup> • FACT-F 13-item subscale <sup>27</sup> • Patient’s Disease and Treatment Assessment Form <sup>21</sup> • Distress Thermometer <sup>22</sup> • Hunger Visual Analogue Scale <sup>36</sup>	X	X	X	X
<b>Physical Activity Behaviour</b> 7-day Actigraph GT1M accelerometers	X		X	X
Participant program evaluation; semi-structured interviews			X	
Adverse Events (CTCAE V4) <sup>37</sup>		X	X	X

BMI= Body mass index

EORTC-QLQC30 = The European Organisation for Research and Treatment of Cancer

1  
2  
3 FBC = full blood count; EUC = electrolytes, urea, creatinine; LFT = liver function  
4 tests ; TSH = Thyroid stimulating hormone; IGF-1 = Insulin-like growth factor -1;  
5 CRP = C-reactive protein  
6 6MWT= six-minute walk test; 1-RM=one repetition maximum  
7 IPAQ-sf=International Physical Activity Questionnaire – short form  
8 EORTC QLQ-C30= The European Organisation for Research and Treatment of  
9 Cancer Quality of Life Questionnaire  
10 FACT-F = Functional Assessment of Cancer Therapy (F= Fatigue)  
11 CTCAE= common terminology criteria for adverse event  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

For peer review only



Figure 1 Referral pathway  
 Figure 1 Referral pathway  
 357x209mm (144 x 144 DPI)

Review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Template for Intervention  
Description and Replication

## The TIDieR (Template for Intervention Description and Replication) Checklist\*:

Information to include when describing an intervention and the location of the information

Item number	Item	Where located **	
		Primary paper (page or appendix number)	Other † (details)
	<b>BRIEF NAME</b>		
1.	Provide the name or a phrase that describes the intervention.	___ Survivorship Clinic p_5-6, 8- _____ Courses p.6-7	___ Protocol paper_____
	<b>WHY</b>		
2.	Describe any rationale, theory, or goal of the elements essential to the intervention.	p._4-7__	_____
	<b>WHAT</b>		
3.	Materials: Describe any physical or informational materials used in the intervention, including those provided to participants or used in intervention delivery or in training of intervention providers. Provide information on where the materials can be accessed (e.g. online appendix, URL).	Questionnaires_ p.10__	_____
4.	Procedures: Describe each of the procedures, activities, and/or processes used in the intervention, including any enabling or support activities.	_p. 4-9	_____
	<b>WHO PROVIDED</b>		
5.	For each category of intervention provider (e.g. psychologist, nursing assistant), describe their expertise, background and any specific training given.	p.5-6__	_____
	<b>HOW</b>		
6.	Describe the modes of delivery (e.g. face-to-face or by some other mechanism, such as internet or telephone) of the intervention and whether it was provided individually or in a group.	___p.8__	_____

TIDieR checklist

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

<b>WHERE</b>		
7.	Describe the type(s) of location(s) where the intervention occurred, including any necessary infrastructure or relevant features.	p. 7-8
<b>WHEN and HOW MUCH</b>		
8.	Describe the number of times the intervention was delivered and over what period of time including the number of sessions, their schedule, and their duration, intensity or dose.	_p.7-12_
<b>TAILORING</b>		
9.	If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, and how.	_p.7-12_
<b>MODIFICATIONS</b>		
10.†	If the intervention was modified during the course of the study, describe the changes (what, why, when, and how).	_N/A_
<b>HOW WELL</b>		
11.	Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, describe them.	_N/A_
12.‡	Actual: If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned.	_N/A_

\*\* **Authors** - use N/A if an item is not applicable for the intervention being described. **Reviewers** – use ‘?’ if information about the element is not reported/not sufficiently reported.

† If the information is not provided in the primary paper, give details of where this information is available. This may include locations such as a published protocol or other published papers (provide citation details) or a website (provide the URL).

‡ If completing the TIDieR checklist for a protocol, these items are not relevant to the protocol and cannot be described until the study is complete.

\* We strongly recommend using this checklist in conjunction with the TIDieR guide (see *BMJ* 2014;348:g1687) which contains an explanation and elaboration for each item.

\* The focus of TIDieR is on reporting details of the intervention elements (and where relevant, comparison elements) of a study. Other elements and methodological features of studies are covered by other reporting statements and checklists and have not been duplicated as part of the TIDieR checklist. When a **randomised trial** is being reported, the

TIDieR checklist

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

TIDieR checklist should be used in conjunction with the CONSORT statement (see [www.consort-statement.org](http://www.consort-statement.org)) as an extension of **Item 5 of the CONSORT 2010 Statement**. When a **clinical trial protocol** is being reported, the TIDieR checklist should be used in conjunction with the SPIRIT statement as an extension of **Item 11 of the SPIRIT 2013 Statement** (see [www.spirit-statement.org](http://www.spirit-statement.org)). For alternate study designs, TIDieR can be used in conjunction with the appropriate checklist for that study design (see [www.equator-network.org](http://www.equator-network.org)).

For peer review only

TIDieR checklist

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



# BMJ Open

## Health status and needs of cancer survivors attending the Sydney Survivorship Centre clinics and programmes: A protocol for longitudinal evaluation of the Centre's services

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014803.R2
Article Type:	Protocol
Date Submitted by the Author:	08-Mar-2017
Complete List of Authors:	Vardy, Janette; University of Sydney, Sydney Medical School; Concord Cancer Centre Tan, Cindy; Concord Repatriation General Hospital, Concord Cancer Centre Turner, Jane; University of Sydney, Centre for Medical Psychology and Evidence-based Medicine Dhillon, Haryana; University of Sydney, Centre for Medical Psychology and Evidence-based Medicine
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Medical management, Nursing, Patient-centred medicine
Keywords:	cancer survivorship, quality of life, survivorship clinic

SCHOLARONE™  
Manuscripts

Health status and needs of cancer survivors attending the Sydney Survivorship Centre  
clinics and programmes: A protocol for longitudinal evaluation of the Centre's  
services

Janette L. Vardy<sup>1,2,3</sup> Cindy Tan<sup>1</sup>, Jane D Turner<sup>1,3</sup>, Haryana M. Dhillon<sup>3</sup>

<sup>1</sup> Concord Cancer Centre, Concord Hospital, Hospital Rd, Concord, NSW,  
Australia

<sup>2</sup> Sydney Medical School, University of Sydney, Concord Hospital, Hospital  
Rd, Concord, NSW, Australia

<sup>3</sup> Centre for Medical Psychology & Evidence-based Decision-making,  
University of Sydney, NSW, Australia

Janette Vardy [janette.vardy@sydney.edu.au](mailto:janette.vardy@sydney.edu.au)

Cindy Tan [cindy.tan@sswahs.nsw.gov.au](mailto:cindy.tan@sswahs.nsw.gov.au)

Jane Turner [jane.turner@sydney.edu.au](mailto:jane.turner@sydney.edu.au)

Haryana Dhillon [Haryana.dhillon@sydney.edu.au](mailto:Haryana.dhillon@sydney.edu.au)

Corresponding author:

Prof. Janette Vardy MD PhD  
Concord Cancer Centre,  
Concord Repatriation General Hospital  
Hospital Rd  
Concord, NSW, 2137  
Australia  
Phone: +61 2 9767 5000  
Fax: +61 2 9767 7934

Email: [janette.vardy@sydney.edu.au](mailto:janette.vardy@sydney.edu.au)

1  
2  
3 Abstract:

4  
5  
6  
7 Introduction:

8  
9  
10 The care of cancer survivors after primary adjuvant treatment is recognised as a  
11 distinct phase of the cancer journey. Recent research highlights the importance of  
12 lifestyle factors in treating symptoms, potentially decreasing risk of a cancer  
13 recurrence, and modifying the risk of developing other chronic illnesses that are  
14 increased in the cancer population. Survivorship services aim to deliver care that  
15 addresses these issues. The overall aims are to determine the health status of cancer  
16 survivors and evaluate the services offered by the Sydney Survivorship Centre.  
17  
18  
19  
20  
21  
22  
23  
24

25 Methods and analysis:

26  
27 An observational, single centre study evaluating the longitudinal physical and  
28 psychological health, symptoms, quality of life, and lifestyle (physical activity and  
29 nutrition) of early-stage cancer survivors attending the multidisciplinary Sydney  
30 Survivorship Clinic and of survivors (at any stage of the cancer journey) and  
31 caregivers participating in Sydney Survivorship Centre courses. Evaluation of patient  
32 satisfaction is included. Patient reported outcomes and patient characteristics will be  
33 summarised using descriptive statistics with Spearman rank sum correlation  
34 coefficients to determine associations between patient-reported outcomes. Regression  
35 modelling may be used to further evaluate associations and to investigate risk factors  
36 and predictors of health outcomes. Qualitative data will be analysed using thematic  
37 analysis to identify themes. Sample size will be determined by attendance of  
38 consenting patients at clinics and courses.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53 Ethics and dissemination:  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The study has received ethics approval from the Concord Repatriation General  
4 Hospital Human Research Ethics Committee (HREC/14/CRGH/23). The results will  
5  
6  
7 be published and presented at appropriate conferences.  
8

9  
10 This study will provide important information regarding the health status and needs of  
11  
12 Australian cancer survivors, and the ability of the Survivorship Centre to address  
13  
14 these needs. These data will shape the future direction of survivorship care in  
15  
16 Australia and facilitate the design of interventions or measures to provide better  
17  
18 quality of care to this patient population.  
19

#### 20 21 22 23 Strengths and Limitations:

##### 24 25 Strengths:

26  
27 -large, longitudinal follow up with comprehensive assessment of health and well-  
28  
29 being of cancer survivors attending a multi-disciplinary Survivorship Centre post  
30  
31 primary adjuvant treatment  
32

##### 33 34 Weaknesses:

35  
36 - observational cohort study  
37  
38 - sample size determined by number of patients attending programme, and giving  
39  
40 consent to deidentified data being used.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Until relatively recently the focus of cancer treatment and research was on the acute treatment of cancer and monitoring for disease recurrence. In 2005 the groundbreaking Institute of Medicine (IOM) Report “Lost in Transition” identified the substantial failure of current follow-up care to comprehensively address the needs of adult cancer survivors.<sup>1</sup> Through the IOM the distinct needs of adult cancer survivors have been recognised along with the importance of helping survivors live with the longer term physical, psychological, and practical effects of cancer and its treatment.<sup>1</sup>

By the broadest definition a person becomes a cancer survivor when they are diagnosed with cancer, a state that continues throughout the remainder of their life.<sup>1</sup>

There are estimated to be more than 25 million cancer survivors worldwide, a number that is projected to increase rapidly due to our ageing population, improved screening leading to earlier detection of cancer, and improvements in cancer treatments.

Even cancer survivors with no evidence of disease recurrence experience greater ongoing health problems than the general population. Cancer survivors are known to be at increased risk of cardiovascular disease, type II diabetes, metabolic syndrome, and osteoporosis, in addition to the risk of a cancer recurrence or a second primary cancer.<sup>1-5</sup> There are a number of identified lifestyle risk factors associated with cancer risk and recurrence, and the chronic diseases that accompany them. These lifestyle risk factors are modifiable and include obesity, physical inactivity, smoking, and inadequate fruit and vegetable intake.<sup>6</sup>

In an attempt to better address the needs of adult cancer survivors some cancer centres have established Survivorship Services, Centres, or Clinics. These services are

1  
2  
3 designed to help survivors and their caregivers better manage their disease and any  
4 lasting effects of treatment, beyond the period of acute diagnosis and treatment.<sup>5</sup> In  
5  
6  
7 addition, many try to facilitate survivors enacting lifestyle changes to increase their  
8  
9  
10 physical activity and maintain a healthy weight, in order to aid recovery, improve  
11  
12 health related quality of life (QOL), and possibly long-term survival.<sup>7</sup> Psychological  
13  
14 support is an important feature of most programmes, and may include psycho-  
15  
16 oncology consultations with a clinical psychologist to manage specific concerns such  
17  
18 as fear of cancer recurrence, anxiety, or depression, general or disease specific  
19  
20 support groups, or counselling support from allied health professionals.<sup>8,9</sup>

21  
22  
23 The IOM recommended, with support of a number of peak bodies including the  
24  
25 American Society of Clinical Oncology (ASCO), that all cancer survivors  
26  
27 transitioning from active to the post treatment phase should receive an individualised  
28  
29 Treatment and Survivorship Care Plan (SCP).<sup>1</sup> This should include a summary of  
30  
31 cancer treatment received, and recommendations regarding future clinical care and  
32  
33 coordination, including the frequency and nature of surveillance based on the best  
34  
35 available evidence. A number of SCP templates are freely available, including generic  
36  
37 and disease specific templates from ASCO and Livestrong, which include information  
38  
39 on potential late and long-term effects from the cancer and/or treatment(s). Despite  
40  
41 recommendations from oncology organisations that SCP should be used, there is  
42  
43 limited evidence that they improve long term outcomes for cancer survivors although  
44  
45 survivor satisfaction with the SCP is generally high.<sup>10</sup>

46  
47  
48  
49 The Sydney Survivorship Centre was established in September 2013 at the Concord  
50  
51 Cancer Centre, in Sydney. It includes: i) a multi-disciplinary survivorship clinic for  
52  
53 patients with localised cancer who have completed primary treatment with curative  
54  
55 intent (e.g. surgery, chemotherapy, and radiation therapy) without evidence of cancer  
56  
57  
58  
59  
60

1  
2  
3 recurrence; and, ii) a range of programmes to support lifestyle change. At the initial  
4  
5 clinic visit patients see a multi-disciplinary team (MDT) comprising a medical  
6  
7 oncologist or haematologist, cancer nurse specialist, dietitian, clinical psychologist,  
8  
9 and accredited exercise physiologist (AEP). Prior to attendance at each clinic,  
10  
11 patients complete a number of questionnaires assessing symptoms, physical activity,  
12  
13 diet, QOL and well-being, and are asked to fill in an evaluation after each clinic.  
14  
15 Education regarding healthy lifestyle and encouragement to maintain a healthy weight  
16  
17 are an important focus of every clinic. An individualised SCP is developed for each  
18  
19 oncology patient.  
20  
21

22  
23 Approximately two thirds of survivors attend the clinic once and then return to their  
24  
25 regular medical team for ongoing follow up. At the request of the caring team, the  
26  
27 remainder continue follow up through the Survivorship Clinic. On subsequent visits  
28  
29 they see the medical oncologist and tumour specific nurse specialist, with referral to  
30  
31 other health professionals and/or programmes as required.  
32  
33

34  
35 In response to the high proportion of survivors who were overweight or obese, and the  
36  
37 increasing evidence supporting obesity as a risk factor for cancer recurrence,<sup>11</sup> we  
38  
39 established a weight management clinic focused on dietary modification, exercise and  
40  
41 behavioural change for those with early stage solid tumours, who have a body mass  
42  
43 index (BMI) >25. The intervention was based on a recent systematic review that  
44  
45 reported dietary modification involving restrictions of energy and fat intake, and  
46  
47 promotion of exercise and behavioural changes were the key components for  
48  
49 successful weight loss and maintenance.<sup>12</sup>  
50  
51

52  
53  
54 The Sydney Survivorship Centre opened the Survivorship Cottage in May 2014. The  
55  
56 cottage is located in the grounds of the hospital, away from the main buildings, and  
57  
58  
59  
60

1  
2  
3 surrounded by gardens and furnished in a homely manner. This is where the majority  
4  
5 of the courses are held for cancer survivors at any stage of their cancer journey, and  
6  
7 their caregivers, with a focus on healthy lifestyle and well-being. The Exercise and  
8  
9 Nutrition Routine Improving Cancer Health (ENRICH)<sup>13</sup> programme is a 6-week  
10  
11 exercise and healthy eating course offered in collaboration with the Cancer Council  
12  
13 New South Wales (NSW) and held regularly throughout the year. Other courses  
14  
15 include: Mindfulness Meditation, Medical QiGong, yoga, acupuncture, music and art  
16  
17 therapy, including scrap-booking, card making, floral design as well as individual  
18  
19 one-off workshops. Courses are selected based on some level of evidence for their  
20  
21 efficacy in cancer survivors.<sup>14-20</sup> The courses are offered weekly for 10 weeks  
22  
23 coinciding with school terms, with 4 terms each year. Commitment to a full term is  
24  
25 required. In addition we provide support groups and public fora on topics of interest  
26  
27 to cancer patients and their caregivers and families.  
28  
29  
30  
31

32  
33 In keeping with the ASCO guidelines,<sup>5</sup> research is an integral component of the  
34  
35 Survivorship Centre. The major research aims of the centre are to: (i) determine the  
36  
37 health status, needs, symptoms, QOL and lifestyle characteristics of cancer survivors  
38  
39 attending the Sydney Survivorship Clinic or participating in courses; (ii) evaluate  
40  
41 changes over time in these variables; (iii) determine risk factors that may affect cancer  
42  
43 survivors' clinical outcomes (e.g. metabolic syndrome, obesity, inactivity); (iv)  
44  
45 evaluate patients' and/or their caregivers/family members' experience with services  
46  
47 offered by the Sydney Survivorship Centre; and (v) evaluate the multidisciplinary  
48  
49 team (MDT) approach in addressing cancer survivors' needs.  
50  
51  
52  
53  
54

## 55 Methods and Analysis

56  
57 This is a single site, longitudinal study led by the Survivorship Research Group  
58  
59  
60



1  
2  
3 (SuRG), University of Sydney and the Sydney Survivorship Centre, Concord Cancer  
4 Centre. Patient reported outcome data are collected as part of standard care and for  
5 quality assurance.  
6  
7  
8  
9

10  
11 *Sydney Survivorship Clinic:*

12 The Sydney Survivorship Centre (SSC) clinic commenced in September 2013.  
13  
14

15  
16  
17 Eligibility:

18  
19 Medical oncology or haematology patients who have completed primary adjuvant  
20 treatment for early stage cancer and have no evidence of a cancer recurrence are  
21 eligible to attend the Survivorship Clinic. Breast cancer patients may be receiving  
22 hormonal treatment and/or targeted therapy such as trastuzumab. Figure 1 depicts the  
23 referral pathway.  
24  
25  
26  
27  
28  
29

30  
31 Procedure:

32  
33 Prior to attending the Survivorship clinic patients are sent a package containing  
34 printed Patient Reported Outcome (PRO) Questionnaires assessing symptoms,  
35 psychological well-being, distress, QOL, physical activity, dietary intake and  
36 performance status. They are asked to bring the completed questionnaires to their  
37 appointment. Those with incomplete questionnaires are asked to finalise them during  
38 the clinic visit. Patients with insufficient English or poor literacy skills can have  
39 assistance from a health translator, family members, or clinic staff during the clinic  
40 appointment.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52 Medical information and weight history are obtained from the medical record.  
53

54 Anthropometry (height and weight) is obtained at the initial visit by clinic staff. A  
55  
56  
57  
58  
59  
60

1  
2  
3 SCP is prepared for oncology patients prior to their initial visit, by either the medical  
4 oncologist or registrar. This plan is refined with the patient after consultation with the  
5 MDT members, and a copy posted to them after the clinic. Haematology patients may  
6 receive a detailed letter from the haematologist with recommendations rather than a  
7 formal Survivorship care plan.  
8  
9

10  
11  
12  
13  
14  
15  
16 Patients are asked to complete an evaluation form after each clinic visit. In addition,  
17 those who have given verbal permission to be contacted subsequently will be asked to  
18 complete a satisfaction survey over the phone or in person to provide feedback on  
19 how useful the Survivorship Care Plan has been, how they used it, and if it has been  
20 revised. This will be approximately 6 months after their initial visit. A subset of  
21 patients will be invited to participate in a qualitative interview to explore, in depth,  
22 their experience of the survivorship service.  
23  
24  
25  
26  
27  
28  
29  
30  
31

### 32 33 34 *Sydney Survivorship Courses:*

35  
36 The courses were gradually introduced from 2014.

### 37 38 Eligibility:

39  
40 Posters advertising the programmes are displayed in the Concord Cancer Centre  
41 waiting areas. Patients with any stage cancer are able to self-refer to participate in  
42 Survivorship courses. Concord Cancer Centre patients receive priority for courses, but  
43 patients from surrounding hospitals are able to attend if space permits. Carers can  
44 accompany a patient and participate if space permits.  
45  
46  
47  
48  
49  
50

### 51 52 Measures used for Survivorship Clinic and Courses: 53 54 55 56 57 58 59 60

1  
2  
3 Outcome measures used in this study are comprehensive assessments of patient self-  
4 report symptoms, QOL, distress, and lifestyle factors. The schedule of assessments  
5 and details of measures are outlined in Table 1.  
6  
7  
8

9  
10  
11 Endpoints:

12  
13 The global aim of this multi-faceted project is to evaluate the Sydney Survivorship  
14 Centre Clinic and Programmes. We aim to assess changes in the endpoints, stated  
15 below, over time:  
16  
17  
18  
19

20  
21 *Survivorship Clinic*

- 22  
23
- 24 • incidence and severity of symptoms that may be associated with cancer and/or  
25 treatment – as assessed by the Patient’s Disease and Treatment Assessment  
26 Form.<sup>21</sup> This is a 48 item questionnaire assessing symptoms with responses  
27 ranging from 0 – 10 (no trouble at all to worst I can imagine) over the  
28 previous month.  
29
  - 30 • distress - as assessed by the Distress thermometer.<sup>22</sup> This asks participants to  
31 rate their level of distress over the previous week from 0 – 10 (no distress to  
32 extreme distress).  
33
  - 34 • quality of life as assessed by the FACT-G.<sup>23</sup> This 27-item questionnaire  
35 assesses physical, social, emotional and functional well-being over the  
36 previous week, with ratings from 0 – 4 (not at all to very much).  
37
  - 38 • physical activity and sedentary behaviour- as assessed by the Active Australia  
39 Exercise Questionnaire<sup>24</sup> and the Sitting Questionnaire<sup>25</sup> and AEP  
40 consultation. Active Australia is a 4-item questionnaire evaluating the time  
41 spent performing physical activity and the intensity of the activity in the  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 previous week. The Sitting questionnaire is a 2-item questionnaire assessing  
4 the time usually spent sitting, on a weekday and on a weekend.  
5  
6

- 7  
8 • dietary intake and behaviour – as assessed by an in-house 3-day food diary  
9 and Food Questionnaire, and dietitian consultation. The 4-item Food  
10 Questionnaire assesses changes made to diet since a cancer  
11 diagnosis/treatment, average number of serves of fruit, vegetables, dairy and  
12 soft drinks daily, and alcohol intake.  
13
- 14 • Eastern Co-operative Oncology Group Performance Status (ECOG  
15 Performance Status)<sup>26</sup> - as assessed by both clinician and participant.  
16
- 17 • Clinical assessments: medical and physical assessment by doctor and nurse;  
18 fear of cancer recurrence assessed by Clinical Psychologist, anthropometric  
19 assessment.  
20
- 21 • Effectiveness of MDT in addressing survivors' needs measured by change in  
22 outcomes, e.g., QOL, sedentary behaviour, etc  
23
- 24 • Use and effectiveness of Treatment and Survivorship Care Plan (SCP). To  
25 determine the incidence of patients attending the Survivorship Clinic who:  
26 receive a survivorship plan; are referred to other health professionals from  
27 clinic; use the SCP (e.g. show other health professionals, carry out the clinic  
28 recommendations). Whether patients found the SCP helpful, did it contain  
29 new information and suggestions for improvement.  
30
- 31 • Clinical progress as determined by results of clinical examination, blood tests  
32 and/or imaging ordered as part of standard of care.  
33
- 34 • Effectiveness of surveillance system: Total number of cases of cancer  
35 recurrence and disease-free survival.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 • Patients' experience with Sydney Survivorship Clinic, developed by the  
4 authors, asking patients to rate how useful the session with each member of  
5 the multidisciplinary team was, and how well their questions were answered.  
6  
7 They also rate how worthwhile it was attending the clinic and give reasons for  
8 their answer, and comment on the length and timing of the clinic in their  
9 cancer journey. Finally they are asked whether they would recommend the  
10 clinic to others and any additional information or services they would have  
11 liked to receive.  
12  
13  
14  
15  
16  
17  
18  
19

20  
21 *Specific SSC programmes:*

22  
23 Weight management programme:

- 24  
25 • Facilitated and supervised by AEP and Dietitian.  
26  
27 • Eligibility: BMI >25; attendance at Sydney Survivorship Clinic, completion of  
28 the ENRICH 6 week lifestyle programme.  
29  
30 • attendance (number of enrolees, proportion completing programmes, reasons  
31 for non-attendance).  
32  
33 • QOL, symptoms, food intake, exercise behaviour, knowledge/practice and  
34 changes compared to baseline assessment.  
35  
36 • Lifestyle outcomes: anthropometry measurements, vital signs, aerobic capacity  
37 and muscular strength - Week 0, 12, 26 and then 6 monthly until 2 years.  
38  
39 • blood results collected as part of standard of care.  
40  
41 • patient experience as measured by a satisfaction survey and interview.  
42  
43  
44  
45  
46  
47  
48

49 See Appendix Table 1 for full details.

50  
51 Mindfulness, QiGong, Yoga, Music therapy, Art therapy or similar courses:

- 52  
53 • Attendance (number of enrolees, proportion completing programmes, reasons  
54 for non-attendance)  
55  
56  
57  
58  
59  
60

- Clinical outcomes: demographics, cancer diagnosis and treatment,
- Symptoms: assessed by the Patient's Disease and Treatment Assessment Form<sup>21</sup>
- Psychosocial outcomes (completed pre and post intervention):
  - QOL and fatigue assessed by the FACT-General (G)<sup>23</sup> and 13-item Fatigue (F) subscale<sup>27</sup>
  - Spiritual well-being assessed by the 12-item FACT-Spiritual<sup>28</sup> (for mindfulness, yoga medical Qigong, acupuncture and medical well-being courses)
  - Symptoms of anxiety and depression –assessed by the Hospital Anxiety and Depression Scale (HADS)<sup>29</sup>
  - Distress – assessed by the Distress Thermometer<sup>22</sup>
- ECOG performance status (patient rated)<sup>26</sup>
- Participant satisfaction questionnaire – at end of programme only

In-depth Qualitative exploration of patient experience:

Cancer survivors and/or caregivers/family members will be invited to participate in focus group(s) and/or interviews to provide in-depth feedback about their experience of SSC services, and information about unmet needs to guide the direction of the SSC clinic or programmes. Both focus groups and telephone interviews are offered to ensure maximum access for individual participants via these flexible options. Consenting individuals will attend a focus group meeting, a face-to-face interview, or a telephone interview with staff of the University of Sydney who are not involved in their clinical care. All interviews are semi-structured, following an ethics approved interview guide developed for the clinic and each programme.

To monitor changing experiences of the clinic over time, groups of attendees will be purposively sampled periodically on the basis of their disease group, side effect profile, and the programmes attended.

Qualitative data will be transcribed verbatim and analysed using thematic analysis.

#### Data analysis and statistical issues

This protocol describes a data collection process that is ongoing as part of service evaluation. The sample included in each analysis will be dependent on the specific questions asked, with specific hypotheses developed prior to analyses, and the sample size determined for each proposed analysis. The sample size will be determined by attendance of consenting patients at clinics and courses. It is estimated that the Survivorship clinic will see 100 new patients per year, of whom 90% will consent to the use of their de-identified data. The first evaluation of initial clinic visits will be performed after 3 years, with an estimated sample size of 300 new patients. This would be considered of clinical significance for determining health status. Approximately 25% of the medical oncology patients receive their follow up at the Survivorship Clinic. We will perform a longitudinal analysis once we have three year follow up for 150 patients. Three year disease free survival is considered a surrogate marker for overall survival for some common tumour types,<sup>30</sup> and this time frame would provide important information on longitudinal health status of survivors.

Outcomes and patient characteristics will be summarised using standard descriptive statistics for each group. Missing data on the PRO will be handled according to the guidelines for each questionnaire. Comparison of results between groups (for example comparing PRO between tumour types) will be performed using Kruskal-Wallis test for continuous variables, Cochran-Armitage test for trend for ordinal variables, and

1  
2  
3 exact  $\chi^2$  tests for categorical variables. Spearman rank sum correlation coefficients  
4  
5 will be used to determine associations between patient-reported outcomes.  
6  
7 Regression modelling may be used to further evaluate associations and to investigate  
8  
9 risk factors and predictors of health outcomes.  
10

11 For longitudinal changes in patient reported outcomes a 10% change in the scale from  
12  
13 baseline will be considered a clinically meaningful change.<sup>31</sup> A comparison of change  
14  
15 over time in symptoms and behaviours will be performed. Changes in PRO at each  
16  
17 time point will be analysed and regression analyses may be subsequently performed  
18  
19 for major health status outcomes, to adjust for variables such as time since treatment  
20  
21 completion and tumour site.  
22  
23

24 Qualitative data analysis: Interview data will be analysed using thematic analysis with  
25  
26 at least two people involved in the analysis. Data coding will occur within a  
27  
28 framework using MS office Excel.<sup>32</sup> Rigour will be ensured through multiple  
29  
30 readings of the data, multiple coders, cross-coding, and member checking of  
31  
32 themes with attendees of the clinic.  
33  
34  
35  
36  
37

### 38 **Discussion:**

39  
40 Survivorship concerns are increasingly recognised as poorly addressed in many  
41  
42 standard follow-up appointments. There is considerable debate and a lack of evidence  
43  
44 regarding how best to follow up cancer survivors. Multi-disciplinary clinics have the  
45  
46 capacity to provide holistic care with a focus on education for lifestyle issues,  
47  
48 prevention of long term side effects and psychological well being; but they are  
49  
50 resource intensive for staff.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 A physically active lifestyle and healthy weight have been shown in observational  
4 studies to decrease the risk of common cancers and cancer recurrence. Studies have  
5 also shown that physical activity and healthy nutrition can improve symptoms  
6 associated with cancer treatment, and decrease the risk of chronic diseases that are  
7 commonly found in cancer survivors; including metabolic syndrome, obesity, type II  
8 diabetes, cardiovascular disease and osteoporosis.<sup>33</sup> Although a number of cancer  
9 organisations have published recommendations regarding exercise and weight, the  
10 majority of cancer patients are overweight or obese, and most do not meet the  
11 guidelines of 150 minutes/week of moderate intensity physical activity, two sessions  
12 of resistance exercise/week and minimising sedentary activities, despite the increasing  
13 evidence for benefit.<sup>33 34</sup> This suggests that cancer survivors require additional  
14 support and education to facilitate their instituting important lifestyle changes.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 The Sydney Survivorship Centre has the potential to improve physical and  
30 psychological well-being and QOL for cancer survivors. This study will obtain unique  
31 data regarding the benefits of a multi-disciplinary team Survivorship clinic for cancer  
32 patients who have completed primary adjuvant treatment, and evaluation of the  
33 courses offered by the Sydney Survivorship Centre for patients at any stage of the  
34 cancer journey and their caregivers/family. This will help determine whether  
35 assessing health status, providing education and lifestyle programmes facilitates  
36 adoption and adherence to a healthy lifestyle, and whether this can lead to  
37 improvement in well-being. Further, it will evaluate the Survivorship care plans  
38 through usage in routine clinical practice, as well as gaining information about who  
39 uses the Sydney Survivorship Centre programmes, and patient (and caregiver)  
40 satisfaction with the clinic and courses.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The strengths of the study are that it will provide a large sample size with longitudinal  
4 follow up with comprehensive assessment of health and well-being of cancer  
5 survivors attending a multi-disciplinary Survivorship Centre post primary adjuvant  
6 treatment. Limitations of the study include that it is an uncontrolled, observational  
7 cohort study, with the sample size dependent on the number of patients attending the  
8 clinic and programmes who consent to their deidentified data being used.  
9  
10  
11  
12  
13  
14  
15

#### 16 17 18 19 Ethics Approval:

20  
21  
22 Ethics approval has been obtained from Concord Repatriation General Hospital  
23 Human Research Ethics Committee (HREC/14/CRGH/23). Patients attending clinics  
24 and courses at the Sydney Survivorship Centre are given the option of a tick box to  
25 “opt out” if they do not wish their de-identified data to be used for research purposes.  
26  
27  
28  
29  
30

#### 31 32 33 34 Dissemination Plan:

35  
36 Study results will be disseminated through a series of peer-reviewed publications and  
37 conference presentations.  
38  
39

#### 40 41 42 43 Data storage and security:

44  
45 Questionnaires are part of standard medical care and are kept in patient’s oncology  
46 subfile. Data are entered into a specifically designed REDCap<sup>TM</sup> database, that is  
47 password protected and kept on a secure University of Sydney website. Records are  
48 identified by a study ID number, and a master list with names is kept separately. Data  
49 can only be accessed by authorised research team members. Data will be retained in  
50 perpetuity after conclusion of the study, and after each patient is discharged from the  
51 Survivorship Service either through completion of follow-up, disease recurrence, or  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 death their data will be fully anonymised by destruction of their details from the  
4  
5 master list.  
6

7 Conclusions:

8  
9 Survivorship services are expanding in Australia and globally. The Sydney  
10 Survivorship Centre is the only multidisciplinary clinic of its kind in Australia. This  
11 study will provide important information about the health status of Australian cancer  
12 survivors, and enable us to better understand the symptoms, lifestyle and risk factors  
13 of our patient population. This will facilitate the design of supportive measures or  
14 interventions to better address these issues.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Author Contributions:

4  
5 J. Vardy: study concept and design, and writing of the protocol and manuscript.  
6 C. Tan: study concept and design, and writing of the protocol and manuscript.  
7 J. Turner: study concept and design, and writing of the protocol and manuscript.  
8 H. Dhillon: study concept and design, and writing of the protocol and manuscript.  
9

10  
11 Competing Interests:

12 None of the authors have any conflicts of interest to declare.  
13

14 Funding Statement:

15  
16 This research is supported by a grant from the National Breast Cancer Foundation,  
17 Australia, in the form of a Practitioner Fellowship to Prof. Janette Vardy. (PRAC-15-  
18 003).  
19

20  
21 Data Sharing:

22 This is a protocol for a longitudinal study so unpublished data are not available for  
23 sharing.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. Hewitt ME, Ganz PA, Institute of Medicine (U.S.), et al. From cancer patient to cancer survivor : lost in transition : an American Society of Clinical Oncology and Institute of Medicine Symposium. Washington, D.C.: National Academies Press 2006.
2. Baade P, Fritschi L, Eakin E. Non-cancer mortality among people diagnosed with cancer (Australia). *Cancer Causes and Control* 2006;17:287-97.
3. Holmes MD, Chen WY, Feskanich D, et al. Physical activity and survival after breast cancer diagnosis. *JAMA* 2005;293(20):2479-86. doi: 10.1001/jama.293.20.2479
4. Meyerhardt JA, Giovannucci EL, Holmes MD, et al. Physical Activity and Survival After Colorectal Cancer Diagnosis. *J Clin Oncol* 2006;24(22):3527-34. doi: 10.1200/jco.2006.06.0855
5. McCabe MS, Bhatia S, Oeffinger KC, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31(5):631-40. doi: 10.1200/JCO.2012.46.6854 [published Online First: 2013/01/09]
6. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington DC: World Cancer Research Fund/American Institute Cancer Research, 2007.
7. Hewitt ME, Greenfield S, Stovall E, et al. From cancer patient to cancer survivor : lost in transition. Washington, D.C.: National Academies Press 2006.
8. Jacobsen PB. Clinical practice guidelines for the psychosocial care of cancer survivors: current status and future prospects. *Cancer* 2009;115(18 Suppl):4419-29. doi: 10.1002/cncr.24589 [published Online First: 2009/09/05]
9. Clinical guidance for responding to suffering in adults with cancer Sydney: Cancer Australia; 2014 [updated June 2014; cited 2016 20th December 2016]. Clinical Guidelines]. accessed December 2016 2016.
10. Kinnane N, Moore, R., Jefford, M., Piper, A., Nolte, L. Survivorship care plans: literature review. Melbourne: Australian Cancer Survivorship Centre, Peter MacCallum, Cancer Centre, 2015.
11. Demark-Wahnefried W, Platz EA, Ligibel JA, et al. The role of obesity in cancer survival and recurrence. *Cancer Epidemiology Biomarkers & Prevention* 2012;21(8):1244-59. doi: 10.1158/1055-9965.epi-12-0485
12. Ramage S, Farmer A, Apps Eccles K, et al. Healthy strategies for successful weight loss and weight maintenance: a systematic review. *Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme* 2014;39(1):1-20. doi: 10.1139/apnm-2013-0026 [published Online First: 2014/01/05]
13. James EL, Stacey FG, Chapman K, et al. Impact of a nutrition and physical activity intervention (ENRICH: Exercise and Nutrition Routine Improving Cancer Health) on health behaviors of cancer survivors and carers: a pragmatic randomized controlled trial. *BMC cancer* 2015;15 doi: 10.1186/s12885-015-1775-y
14. Buffart LM, van Uffelen JG, Riphagen, II, et al. Physical and psychosocial benefits of yoga in cancer patients and survivors, a systematic review and meta-analysis of randomized controlled trials. *BMC cancer* 2012;12:559. doi: 10.1186/1471-2407-12-559 [published Online First: 2012/11/28]

15. Lengacher CA, Reich RR, Paterson CL, et al. Examination of Broad Symptom Improvement Resulting From Mindfulness-Based Stress Reduction in Breast Cancer Survivors: A Randomized Controlled Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2016;34(24):2827-34. doi: 10.1200/JCO.2015.65.7874 [published Online First: 2016/06/02]
16. Tao WW, Jiang H, Tao XM, et al. Effects of Acupuncture, Tuina, Tai Chi, Qigong, and Traditional Chinese Medicine Five-Element Music Therapy on Symptom Management and Quality of Life for Cancer Patients: A Meta-Analysis. *Journal of pain and symptom management* 2016;51(4):728-47. doi: 10.1016/j.jpainsymman.2015.11.027 [published Online First: 2016/02/18]
17. Zhou K, Li X, Li J, et al. A clinical randomized controlled trial of music therapy and progressive muscle relaxation training in female breast cancer patients after radical mastectomy: results on depression, anxiety and length of hospital stay. *European journal of oncology nursing : the official journal of European Oncology Nursing Society* 2015;19(1):54-9. doi: 10.1016/j.ejon.2014.07.010 [published Online First: 2014/09/04]
18. Chiu HY, Shyu YK, Chang PC, et al. Effects of Acupuncture on Menopause-Related Symptoms in Breast Cancer Survivors: A Meta-analysis of Randomized Controlled Trials. *Cancer nursing* 2016;39(3):228-37. doi: 10.1097/NCC.0000000000000278 [published Online First: 2015/06/08]
19. Oh B, Butow P, Mullan B, et al. Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2010;21(3):608-14. doi: 10.1093/annonc/mdp479 [published Online First: 2009/11/03]
20. Wood MJ, Molassiotis A, Payne S. What research evidence is there for the use of art therapy in the management of symptoms in adults with cancer? A systematic review. *Psycho-oncology* 2011;20(2):135-45. doi: 10.1002/pon.1722 [published Online First: 2010/09/30]
21. Stockler MR, O'Connell R, Nowak AK, et al. Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. *The lancet oncology* 2007;8(7):603-12. doi: 10.1016/S1470-2045(07)70148-1
22. Tuinman MA, Gazendam-Donofrio SM, Hoekstra-Weebers JE. Screening and referral for psychosocial distress in oncologic practice: use of the Distress Thermometer. *Cancer* 2008;113(4):870-8. doi: 10.1002/cncr.23622 [published Online First: 2008/07/12]
23. Cella D, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. *J Clin Oncol* 1993;11(3):10.
24. Brown WJ, Trost SG, Bauman A, et al. Test-retest reliability of four physical activity measures used in population surveys. *J Sci Med Sport* 2004;7(2):11.
25. Marshall AL, Miller YD, Burton NW, et al. Measuring total and domain-specific sitting: a study of reliability and validity. *Med Sci Sports Exerc* 2010;42(6):9.
26. Oken MM, Creech RH, Tormey DC. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982;5(6):7.
27. Yellen SB, Cella D, Webster K, et al. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. *J Pain and Symptom Management* 1997;13(2)



- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
28. Peterman AH, Fitchett G, Brady MJ, et al. Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy--Spiritual Well-being Scale (FACIT-Sp). *Annals of behavioral medicine : a publication of the Society of Behavioral Medicine* 2002;24(1):49-58. [published Online First: 2002/05/15]
29. Bjelland I, Dahl AA, Haug TT, et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *Journal of psychosomatic research* 2002;52(2):69-77. [published Online First: 2002/02/08]
30. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2005;23(34):8664-70. doi: 10.1200/JCO.2005.01.6071
31. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. *J Clin Oncol* 1998;16(1):139-44.
32. Pope C, Ziebland S, Mays N. Qualitative research in health care. Analysing qualitative data. *BMJ* 2000;320(7227):114-6.
33. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. *CA Cancer J Clin* 2012;62(4):243-74. doi: 10.3322/caac.21142 [published Online First: 2012/04/28]
34. Schmitz KH, Courneya KS, Matthews C, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. *Medicine and science in sports and exercise* 2010;42(7):1409-26. doi: 10.1249/MSS.0b013e3181e0c112 [published Online First: 2010/06/19]
35. Groenvold M, Klee MC, Sprangers MAG, et al. Validation of the EORTC QLQ-C30 Quality of Life Questionnaire through combined qualitative and quantitative assessment of patient-observer agreement. *Journal of Clinical Epidemiology* 1997;50(4):441-50.
36. Caudwell P, Gibbons C, Hopkins M, et al. The influence of physical activity on appetite control: an experimental system to understand the relationship between exercise-induced energy expenditure and energy intake. *The Proceedings of the Nutrition Society* 2011;70(2):171-80. doi: 10.1017/S0029665110004751 [published Online First: 2011/01/14]
37. Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, 2009.

## Acknowledgements

We would like to acknowledge our thanks to the following people for their assistance with database design and entry:

Database design: Anne Warby

Data entry: Erika Jungfer, Loraine Fong and Christopher Mo.

For peer review only



1  
2  
3 Figure Legend  
4

5 Figure 1 Referral pathway through the Sydney Survivorship Clinic, centre and  
6 courses  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 1 Schedule of assessments for patients attending the Sydney Survivorship Clinic or participating in Sydney Survivorship Centre courses:**

a) Sydney Survivorship Clinic

	Assessment	Initial visit	Follow Up*
	Demographics and cancer/ cancer treatment characteristics	X	
	Clinical examination	X	X
	Anthropometry <ul style="list-style-type: none"> <li>• Weight</li> <li>• Weight history</li> </ul>	X X	X
	Blood tests: As per standard of care e.g. colorectal cancer survivors: CEA every 3 months Other blood tests only as clinically indicated	X	X
	Imaging/Procedures: As per ASCO guidelines Breast cancer: Mammogram and/or breast ultrasound annually. Colorectal cancer: CT chest/abdomen/pelvis annually for 5 years. Colonoscopy: 1 year after diagnosis then 1-2 yearly dependent on result  Results of other procedures as ordered by oncology team as part of standard of care.	X	X
Patient Reported Outcomes	Distress (Distress Thermometer) <sup>22</sup>	X	X
	Symptoms (Patient's Disease and Treatment Assessment Form) <sup>21</sup>	X	X
	Sedentary time (Sitting Questionnaire) <sup>25</sup>	X	X*
	Physical activity (Active Australia Questionnaire) <sup>24</sup>	X	X*
	3-day food diary and food questionnaire	X	X*
	Quality of Life questionnaire (FACT-G) <sup>23</sup>	X	X*
	ECOG performance status <sup>26</sup>	X	X
Evaluation	SSC Feedback Questionnaire	X	
	SSC Satisfaction survey		X
	Treatment and Survivorship Plan evaluation		X*

\*Follow up will be individualised depending on tumour type and stage of disease but will generally be every 3-6 months. With the exception of the distress thermometer, Patients Disease and Treatment assessment form and the self-rated performance status, questionnaires will not be completed more frequently than every 6 months.

b) Courses for Sydney Survivorship Centre

Assessment	Initial Visit	Conclusion of Programme
Baseline demographics and disease characteristics	X	
Questionnaires:		
• FACT-G <sup>23</sup>	X	X
• FACT-fatigue (F) subscale <sup>27</sup>	X	X
• FACT Spirituality (Sp) subscale* <sup>28</sup>	X	X
• Patient's Disease and Treatment Assessment Form <sup>21</sup>	X	X
• Distress Thermometer <sup>22</sup>	X	X
• Hospital Anxiety and Depression Scale (HADs) <sup>29</sup>	X	X
Participant evaluation	X	X

\* Only for Medical Qigong, yoga, mindfulness, acupuncture and music and well-being

SSC = Sydney Survivorship Centre

CEA = Carcinoembryonic Antigen; ASCO= American Society of Clinical Oncology;

FACT = Functional Assessment of Cancer Therapy (G= general; F= Fatigue; Sp = spirituality)

**Appendix Table 1 - Schedule of assessments for patients attending the Sydney Survivorship “Weight Management Course”**

Assessment	Baseline	3 Month	6 Month	12 Month
Baseline demographics and disease characteristics, weight history	X			
<b>Clinical examination</b> (accredited exercise physiologist, dietitian, physician)	X	X	X	X
<b>Body Composition</b> Bioimpedance analysis, skinfold measures, girth measures, BMI	X	X		
DEXA scan (where appropriate)	X			X
<b>Fasting blood tests</b> FBC, EUC, LFT, glucose, lipids, iron studies, sex hormones, vitamin D, vitamin B12, TSH, IGF-1, CRP, albumin  Other bloods as appropriate when ordered as standard of care	X	X	X	X
<b>Physical Function</b> 6MWT and/or Graded Sub-maximal Exercise Test; Maximal 1-RM leg press; Hand grip dynamometry	X	X	X	X
<b>Nutritional Status</b> 3-day weighed food diary	X	X	X	X
<b>Patient Reported Outcomes</b> • IPAQ-sf <sup>24</sup> • EORTC-QLQ-C30 <sup>35</sup> • FACT-F 13-item subscale <sup>27</sup> • Patient’s Disease and Treatment Assessment Form <sup>21</sup> • Distress Thermometer <sup>22</sup> • Hunger Visual Analogue Scale <sup>36</sup>	X	X	X	X
<b>Physical Activity Behaviour</b> 7-day Actigraph GT1M accelerometers	X		X	X
Participant program evaluation; semi-structured interviews			X	
Adverse Events (CTCAE V4) <sup>37</sup>		X	X	X

BMI= Body mass index

EORTC-QLQC30 = The European Organisation for Research and Treatment of Cancer

1  
2  
3 FBC = full blood count; EUC = electrolytes, urea, creatinine; LFT = liver function  
4 tests ; TSH = Thyroid stimulating hormone; IGF-1 = Insulin-like growth factor -1;  
5 CRP = C-reactive protein  
6 6MWT= six-minute walk test; 1-RM=one repetition maximum  
7 IPAQ-sf=International Physical Activity Questionnaire – short form  
8 EORTC QLQ-C30= The European Organisation for Research and Treatment of  
9 Cancer Quality of Life Questionnaire  
10 FACT-F = Functional Assessment of Cancer Therapy (F= Fatigue)  
11 CTCAE= common terminology criteria for adverse event  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

For peer review only




Figure 1 Referral pathway  
 Figure 1 Referral pathway  
 254x190mm (300 x 300 DPI)

ew only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Template for Intervention  
Description and Replication

## The TIDieR (Template for Intervention Description and Replication) Checklist\*:

Information to include when describing an intervention and the location of the information

Item number	Item	Where located **	
		Primary paper (page or appendix number)	Other † (details)
	<b>BRIEF NAME</b>		
1.	Provide the name or a phrase that describes the intervention.	___ Survivorship Clinic p_5-6, 8- _____ Courses p.6-7	___ Protocol paper_____
	<b>WHY</b>		
2.	Describe any rationale, theory, or goal of the elements essential to the intervention.	p. _4-7__	_____
	<b>WHAT</b>		
3.	Materials: Describe any physical or informational materials used in the intervention, including those provided to participants or used in intervention delivery or in training of intervention providers. Provide information on where the materials can be accessed (e.g. online appendix, URL).	Questionnaires_ p.10__	_____
4.	Procedures: Describe each of the procedures, activities, and/or processes used in the intervention, including any enabling or support activities.	_p. 4-9	_____
	<b>WHO PROVIDED</b>		
5.	For each category of intervention provider (e.g. psychologist, nursing assistant), describe their expertise, background and any specific training given.	p.5-6__	_____
	<b>HOW</b>		
6.	Describe the modes of delivery (e.g. face-to-face or by some other mechanism, such as internet or telephone) of the intervention and whether it was provided individually or in a group.	___p.8__	_____

TIDieR checklist

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



<b>WHERE</b>		
7.	Describe the type(s) of location(s) where the intervention occurred, including any necessary infrastructure or relevant features.	p. 7-8
<b>WHEN and HOW MUCH</b>		
8.	Describe the number of times the intervention was delivered and over what period of time including the number of sessions, their schedule, and their duration, intensity or dose.	_p.7-12_
<b>TAILORING</b>		
9.	If the intervention was planned to be personalised, titrated or adapted, then describe what, why, when, and how.	_p.7-12_
<b>MODIFICATIONS</b>		
10.†	If the intervention was modified during the course of the study, describe the changes (what, why, when, and how).	_N/A_
<b>HOW WELL</b>		
11.	Planned: If intervention adherence or fidelity was assessed, describe how and by whom, and if any strategies were used to maintain or improve fidelity, describe them.	_N/A_
12.‡	Actual: If intervention adherence or fidelity was assessed, describe the extent to which the intervention was delivered as planned.	_N/A_

\*\* **Authors** - use N/A if an item is not applicable for the intervention being described. **Reviewers** – use ‘?’ if information about the element is not reported/not sufficiently reported.

† If the information is not provided in the primary paper, give details of where this information is available. This may include locations such as a published protocol or other published papers (provide citation details) or a website (provide the URL).

‡ If completing the TIDieR checklist for a protocol, these items are not relevant to the protocol and cannot be described until the study is complete.

\* We strongly recommend using this checklist in conjunction with the TIDieR guide (see *BMJ* 2014;348:g1687) which contains an explanation and elaboration for each item.

\* The focus of TIDieR is on reporting details of the intervention elements (and where relevant, comparison elements) of a study. Other elements and methodological features of studies are covered by other reporting statements and checklists and have not been duplicated as part of the TIDieR checklist. When a **randomised trial** is being reported, the

TIDieR checklist

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

TIDieR checklist should be used in conjunction with the CONSORT statement (see [www.consort-statement.org](http://www.consort-statement.org)) as an extension of **Item 5 of the CONSORT 2010 Statement**.  
When a **clinical trial protocol** is being reported, the TIDieR checklist should be used in conjunction with the SPIRIT statement as an extension of **Item 11 of the SPIRIT 2013 Statement** (see [www.spirit-statement.org](http://www.spirit-statement.org)). For alternate study designs, TIDieR can be used in conjunction with the appropriate checklist for that study design (see [www.equator-network.org](http://www.equator-network.org)).

For peer review only

TIDieR checklist

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>